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ABSTRACT 
Cancer, a complicated disease, results from various causes including abnormal 
overexpression of oncogene products. The c-myc gene was found as the cellular homolog of 
v-myc oncogene. Its deregulated expression can result in a wide range of tumors in human and 
mouse. c-Myc, as a transcription factor, requires the Max protein to form a heterodimer that 
binds to its target DNA sequence, CACGTG, termed an E box, to drive some cancer-related 
downstream gene expression. Here a strategy of developing DNA aptamer(s) using SELEX 
(Systemic Evolution of ligands by Exponential Enrichment) was performed to isolate 
single-stranded DNA molecules that could recognize the c-Myc:Max protein and inhibit 
c-Myc's activity in vitro and in vivo, and therefore to develop a new type of reagent for cancer 
therapy.  
Aptamers are small single-stranded DNA or RNA molecules that can bind to a wide 
range of targets from small molecules, such as ATP, to proteins and even to whole cells, with 
high specificity and affinity. In the procedure of SELEX, we attempted to combine the 
“decoy” approach to develop an anti-c-Myc aptamer. In the design of the original pool, we put 
a complement of the E box into the 5’ primer followed by a 42 base random sequence. We 
expected that the selected anti-c-Myc aptamer includes a primary c-Myc binding site that may 
include a loop-like structure. We also expected that the other complement of E box would be 
selected from the random region and form a stem structure with the one included in the 5’ 
primer. This E box could then bind to the E box binding domain of the c-Myc:Max 
heterodimer. So the expected anti-c-Myc aptamer would bind to the target protein by two 
mechanisms - primary aptamer binding and decoy. The combination of primary binding site 
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of the aptamer to c-Myc:Max and the interaction between the decoy component with 
c-Myc:Max will make the affinity of the anti-c-Myc aptamer higher than only with one 
primary binding site or only with the E box. 
The data we obtained suggest that the single-stranded DNA aptamers prepared by this 
“decoy” method, including full length and truncated sequences, can bind to the c-Myc:Max 
heterodimer with very high affinity (Kd’s from 100-500 nM) and specificity for the target 
protein, but can not compete with the E box sequence to bind to c-Myc:Max. It was interesting 
to find that none of the single-stranded DNA molecules we selected included E box sequence, 
which means that the selected DNA molecules bind to c-Myc:Max at some other sites instead 
of an E box binding domain. 
There are several directions we could go to optimize the current selected DNA 
molecules so as to develop anti-c-Myc aptamers. First, we could gradually truncate the current 
aptamers to determine the minimum sequences for each aptamer. Second, an extra E box 
sequences could be linked to the DNA sequences by rational design to increase the binding 
affinity. Third, some random mutations could be introduced into the previously selected DNA 
sequences by doping. Doping means that when the candidate aptamers were synthesized, the 
percentage of the four bases, A, T, C and G, is not evenly distributed among each position, so 
some random variations will be added to the original aptamer sequences. By introducing the 
new mutations, certain members of the degenerate aptamer pool could have higher binding 
affinity to target protein than the starting aptamer.         
  
1
 
INTRODUCTION 
Thesis organization 
My work was mainly focused on the development of single-stranded DNA aptamers 
for c-Myc:Max heterodimer, including preparation of the active protein targets, selection of 
ssDNA aptamers against c-Myc:Max using SELEX (Systematic Evolution of Ligands by 
EXponential enrichment), checking the binding ability of selected oligonucleotides to bind 
c-Myc:Max by EMSA (electrophoretic mobility shift assay). The work that I focused on was 
part of a collaborative project. Another main participator was Marjan Mokhtarian. Both of us 
did two SELEX experiments in parallel. Marjan Mokhtarian's work also included testing the 
binding affinity of selected oligonucleotides using a filter capture assay and estimating the Kd 
of these molecules by the filter capture assay. 
In the “introduction”, I discuss the c-Myc:Max protein heterodimer including its 
structure and various functions in vivo including the effects on cell cycle progression, genomic 
stability, apoptosis and cellular metabolism etc. Following that, I introduce some 
characteristics of the aptamers, single-stranded DNA or RNA molecules that can bind various 
targets with high affinity and specificity. A comparison of aptamers and antibodies is 
discussed to demonstrate the advantages of aptamer molecules over antibody. The 
applications of aptamers in diagnostics and therapeutics are also discussed. The third part of 
the introduction discusses the establishment and development of SELEX, the method we used 
to isolate the c-Myc:Max aptamer.  
Subsequent section in the thesis are “Materials and Methods” followed by “Results 
and Discussion”, then “Conclusions and Future directions”. The next section is the 
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“Appendix”, which contains some early works related to the project including some data of 
subcloning of the c-Myc and Max cDNAs, protein expression and purification, and EMSA. 
Finally, the references used in the thesis are listed.  
The structure and function of c-Myc:Max 
A critical member of the myc proto-oncogenes, c-myc was discovered in the chicken 
as a homologous gene of the v-myc oncogene, which is from a retrovirus that can induce 
myeloid leukemia, sarcomas, liver, and kidney tumors in the chicken (Dang 1999). The c-myc 
gene is widely distributed in organisms, ranging from human to mice, birds, amphibians, fish 
and Drosophila (Littlewood 1998). Besides c-myc, the myc gene family also includes B-myc, 
L-myc, N-myc and s-myc. Only c-myc, L-myc and N-myc have oncogenic potential (Dang et 
al. 1999). 
The Myc protein, known as one of the central pillars of carcinogenesis, belongs to 
bHLHZ proteins in structure. The structure of this protein family is shown in figure 1. Myc, as 
a DNA binding transcription factor, contains a helix-loop-helix (HLH) motif at its C-terminus, 
which is a dimerization domain that can mediate heterodimerization of Myc with Max (Myc 
association factor X). Max is another HLH protein that can play other important functions in 
vivo. For c-Myc and Max, there is a short region consisting of basic amino acid residues N 
terminal to the HLH domain that mediates the specific interaction between the c-Myc:Max 
protein and its target DNA sequence (CACGTG), which is called an E box. The critical amino 
acids in the basic region that bind to the E box include glutamic acid (the 9th residue), which 
contacts the CA of the E box, and an arginine residue that interacts with the internal G of the E 
box sequence. Besides the HLH and basic region the transcription factor heterodimer contains 
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another dimerization domain immediately adjacent to C-terminus of the HLH domain, which 
is the leucine zipper (Littlewood 1998). 
The N-terminus of Myc protein also plays important roles in transcriptional regulation 
of Myc. There exist two conserved sequences among the Myc family protein that are termed 
MBI and MBII (Myc box I and II). MBI is the glycosylation and phosphorylation site of Myc. 
The first 143 amino acids at the N-terminus are necessary for Myc:Max binding to its target 
DNA sequence and transcriptional activation, so it is called the transcriptional activation 
domain (TAD) (Kato et al. 1990).        
Several important factors affect the interaction between the Myc-Max heterodimer 
with the E box. These include: 1) the flanking sequences immediately before and after 
CACGTG. Generally G/C dinucleotides predominate over other nucleotides on both sides of 
the E box sequence; 2) Methylation of CpG of the E box. When the cytosine at the CpG motif 
is methylated by DNA methyl-transferase, it will inhibit Myc binding to the E box in vitro and 
in vivo; 3) Other transcription factors that could affect the heterodimer’s binding (Grandori et 
al. 2000). 
When regulating target genes’ transcription, the N-terminal of Myc protein interacts 
with a variety of proteins involved in transcription. TRRAP is one of earliest found cofactors 
of Myc:Max, which binds to the TAD of Myc. After binding to the N-terminus of Myc, 
TRRAP recruits histone acetylase GCN5 and histone acetyl transferase Tip 60 to the promoter 
of Myc target genes, which may change the structure of chromatin to recruit more  other 
transcription factors including TFIIE or TBP to drive the Myc target genes' transcription 
(Brough et al. 1995; McMahon et al. 2000). 
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Besides Myc, the Max protein also can bind to other proteins in HLH family. 
Max-interacting bHLH proteins include members of the Mad protein family, Mnt (or called 
Rox) and Mga. Like Myc, these Max protein partners also interact with Max by the HLH 
domain, but act as repressors and promote cell terminal differentiation instead of cell 
proliferation by binding the E box sequences. The Max protein itself can form homodimers 
and repress target gene transcription by binding the same DNA sequences as do other Max 
heterodimers. So Max, as a stable (t 1/2 ~ 24h ), ubiquitously expressed protein can dimerize 
with various regulated protein partners to form different complexes that either activate or 
repress specific target gene transcription and control a series of cellular behaviors (Grandori et 
al. 2000).   
Based on the studies of the last two decades, it is known that, in normal cells, the 
c-Myc gene expression is tightly regulated in response to diverse signals including growth 
factors, cytokines and mitogens (Dang 1999; Grandori et al. 2000). The expression of c-Myc 
in normal cells is strongly correlated with cell growth and proliferation. Homologous 
recombination studies showed that deletion of both alleles of the c-myc gene can cause mouse 
embryos to die between 9.5 and 10.5 days of gestation (Davis et al. 1993), which proved that 
normal regulated c-Myc expression is required for embryonic development. Another 
experiment showed the consequence of a remarkable prolongation of cell doubling time in 
immortalized rat fibroblasts with c-myc inactivation, which demonstrated that Myc is 
involved in the mechanism of controlling cell and tissue growth and proliferation (Mateyak et 
al. 1997).  
On the other hand, the c-Myc gene is overexpressed in many cancer cells in an 
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uncontrolled way and causes various pathological changes, including lung carcinoma, breast 
carcinoma, cervical carcinoma, ovarian carcinoma and a variety of hematological tumors 
(Dang et al. 1999). Two main mechanisms have been found that cause abnormal expression 
and/or regulation of c-Myc protein. One is chromosomal translocation. The c-Myc gene is 
translocated  from chromosome 8 to a position downstream of the promoters of one of three 
immunoglobulin genes that are on chromosome 2,14 or 22 and is then constitutively activated 
(Boxer and Dang 2001; Dang et al. 1999). The other reason for Myc activation is due to point 
mutations that occur in the region around its phosphorylation and glycosylation sites in the 
transactivation domain at its amino terminus. These mutations affect normal modifications in 
the N terminus, abolish negative regulation of c-Myc activity and prolong the half-life of the 
onco protein (Dang et al. 1999). 
Deregulated expression of Myc has significant effects on several related cellular 
behaviors by activating or repressing specific target genes. These cellular activities include 
cell cycle progression, differentiation, genomic stability, apoptosis and cellular metabolism 
(Dang et al. 1999). The effects of Myc on these cellular behaviors may be linked to its 
oncogenic activity.   
For cell cycle control, constitutive expression of c-Myc mainly drives cell cycle 
progression from G1 to S phase (Karn et al. 1989). A series of important molecular events 
occur in this period. The best identified event is the inactivation of the Retinoblastoma protein 
(pRb) through phosphorylation by cyclin-dependent kinases (CDKs) (Roussel 1997). The 
phosphorylated pRb dissociates from transcription factor E2F proteins, following which the 
released E2F proteins drive their target genes' expression. The target genes include cyclin E 
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and A, which are required for S phase entry. Myc, as a positive regulator of CDK, can increase 
cyclin E/CDK2 or cyclin E activity via three distinct pathways. The first is functional 
inactivation of p27 to prevent p27-mediated growth arrest (Amati et al. 1998; Dang et al. 
1999). P27 is one of the main anti-proliferation signals. Constitutively expressed Myc 
indirectly antagonizes the function of p27 and makes it dissociate from cyclin E/CDK2 
(Amati et al. 1998). Studies using Myc-estrogen receptor (MycER) chimeras indicated 
another way that Myc up-regulates cyclin E expression. The activation of Myc in this study 
increased cyclin E expression at the transcription level. No other factors were involved, which 
suggests that cyclin E gene may be a direct target of Myc. But further evidence is needed to 
support this hypothesis (Amati et al. 1998). The third pathway of cell cycle control by Myc is 
through phosphatase Cdc25A. The Cdc25A gene is positively regulated by Myc. Cdc25 A 
dephosphorylates and actives CDK2. Active CDK2 drives downstream events of cell cycle 
progression from G1 to S phase (Amati et al. 1998; Dang et al. 1999). Colony stimulating 
factor (CSF-1) is required for some cell lines to enter into S phase. Myc is an immediate early 
response gene of CSF-1. CSF-1 needs to bind its receptor (CSF-1R) to initiate the mitogenic 
response via different pathways. Roussel et al., (1997) used NIH-3T3
fibroblasts to show that the tyrosine at position 809 in CSF-1R plays key roles to keep 
cells surviving and proliferating. Engineered human CSF-1R point mutant (CSF-1R Y809F) 
expressed in NIH-3T3 fibroblasts can produce a considerable reduction in Myc expression, 
which suggests that Myc is tightly linked to CSF-1-dependent proliferation (Roussel 1997). 
Besides transcriptional activation by Myc of specific target genes, Myc also promotes 
cell proliferation and oncogenesis via transcriptional repression of some cell cycle/growth 
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inhibitors, especially repression of transforming growth factor-β (TGF-β) -induced growth 
arrest. These cell cycle arrest genes include p15, p21, p27, gas1 (growth arrest specific1), 
Gadd (growth arrest and DNA damaging-inducible) genes (Gartel and Shchors 2003; Wanzel 
et al. 2003). Basically constitutive expression of Myc represses gene transcription via two 
different mechanisms. One involves the Myc-Max heterodimer and the Inr (transcriptional 
initiator) element. In this model the Myc-Max heterodimer interacts with Miz-1 (a zinc-finger 
protein and a partner of Myc) or another transcriptional activator through the c-terminal 
domain of Myc; the Myc-Max-Miz-1 complex binds to the Inr element of the target genes to 
suppress their expression. The other mechanism is Sp1-instead of Inr-dependent. In this model 
Myc interacts with Sp1 only or with active Smad2/3 and Sp1 to form an inactive stable 
complex of Sp1-Smad-c-Myc through the central domain of Myc; it is not necessary for Myc 
to bind Max and the DNA element (Gartel and Shchors 2003). The cell cycle inhibitor P15 
gene is a good example that is repressed by Myc through both mechanisms. P21 is a CDK 
inhibitor that is suppressed by c-Myc via an Inr-independent mechanism. Microarray analysis 
showed that P21 is a direct transcriptional repression target of c-Myc. The CDK inhibitor P27 
is repressed by c-Myc through the c-Myc-Max heterodimer binding to the Inr element of the 
p27 promoter (Gartel and Shchors 2003). The c-Myc also represses transcription of the Gas1 
gene although the molecular mechanism is not well understood. It has been reported that the 
Myc box2 (MBII) is required for this repression (Lee et al. 1997). It has also been shown that 
GADD 45 is suppressed by c-Myc through its binding to the GC-rich binding site of the 
GADD45 promoter via the Sp1 Inr-independent pathway (Wilson 1997). So in conclusion, 
loss of transcriptional repression of cell cycle/growth arrest genes by Myc is a very important 
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way by which Myc promotes proliferation and the neoplastic phenotype. 
Tumorigenesis induced by the overexpression of Myc is also reflected by genomic 
instability. Transient excess of Myc can increase the occurrence of the neoplastic phenotype of 
Rat1A cells by 50-fold and that this phenomenon is accompanied by destabilization of the 
cellular genome (Dang et al. 1999; Felsher and Bishop 1999; Mai et al. 1996). The genomic 
instability is reflected by multiple chromosomal abnormalities, such as aneuploidy, double 
minute chromosomes, dicentric chromosomes and multicentric chromosomes. The authors 
demonstrated that Myc may induce genomic instability by destroying the G1/S check points 
for DNA damage thus allowing the cell cycle to continue before the cells can adequately 
respond to the damage. This can promote the accumulation of DNA damage in the cell 
(Felsher and Bishop 1999). Genomic instability is also found in NIH 3T3 cells (Felsher and 
Bishop 1999) and mammary gland tumor cells of transgenic mice when c-Myc is 
overexpressed (McCormack et al. 1998). 
Myc overexpression was also found to link to programmed cell death or apoptosis. The 
relationship between c-Myc and apoptosis was first found in 32D.3 myeloid progenitor cells, 
(Askew et al. 1991). Other studies showed that overexpressed c-Myc in Rat-1 fibroblast 
(Hermeking and Eick 1994), mouse mammary gland cells (McCormack et al. 1998) or 
activated myc-ER in mouse primary embryo fibroblast (Wagner et al. 1994) could lead to 
apoptosis. On the other hand c-Myc overexpression induces immortalization of primary 
rodent fibroblasts (Land et al. 1983; Simm et al. 1994). The main mechanism by which c-Myc 
induces immortalization is by driving the expression of telomerase hTERT, which maintains 
the length of telomeres and causes cell immortalization. The c-Myc binding sequence (E box) 
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was found in the promoter of the hTERT gene, which suggests it could be directly activated by 
c-Myc (Horikawa et al. 1999; Wu et al. 1999). 
Deregulated expression of c-Myc also affects cell metabolism as reflected by changing 
energy consumption, DNA metabolism and translational regulation. In tumor tissues, cancer 
cells usually utilize glucose as main source of energy instead of oxygen and they produce 
lactic acid. This phenomenon is termed the “Warburg effect” (Dang and Semenza 1999). The 
lactate dehydrogenase-A (LDHA) gene is tightly related to the “Warburg effect”, and its 
activity is regulated by c-Myc (Tavtigian et al. 1994). Also c-Myc-related transformation 
requires LDHA overexpression (Shim et al. 1997). Besides LDHA, other c-Myc-responsive 
genes include the ornithine decarboxylase (ODC) (Packham and Cleveland 1995), 
dihydrofolate reductase (Mai and Jalava 1994) and thymidine kinase (Pusch et al. 1997) genes. 
The enzymes encoded by these genes participate in DNA metabolism, which makes it easier to 
understand c-Myc protein mediated cell cycle progression from G1 to S phase, because DNA 
synthesis occurs in S phase. The effects of c-Myc on cell metabolism also include the 
regulation by c-Myc of several translational initiation factor encoding genes including the 
eIF-2α gene (Rosenwald et al. 1993), Eif-4E (Jones et al. 1996) and ECA39 (Benvenisty et al. 
1992). 
The deregulated c-Myc gene expression in various cancer cells suggests that this 
oncogene could be regarded as a potential target of cancer therapy. Traditional approaches of 
inhibiting oncogene activity have some limitations, such as toxicity due to long time 
inhibition of associated proto-oncogenes, and the potential of tumor regrowth caused by 
cessation of the pharmacologic inhibition of target oncogenes. Jain and colleagues used the 
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tetracycline-regulated system to control the expression of Myc in transgenic mice and used 
doxycycline as an inhibitor to stop Myc expression in osteogenic sarcoma cells transplanted 
into syngeneic mice (Jain et al. 2002). The data showed that within twenty-four hours of 
treating with doxycycline, osteogenic sarcoma cells differentiated into mature osteocytes. 
What's more, after Myc expression in osteocytes was reactivated by removing the inhibitor, 
the cells did not restore their malignant properties but went into apoptosis. So even a brief 
inactivation of c-Myc (24 hours) could result in a sustained regression of tumors in mice. 
Strategies of inhibiting c-Myc's activity in cancer cells could focus on the gene, mRNA 
or protein levels. Triple-helix forming oligo nucleotides (TFOs) inhibit gene transcription by 
blocking the binding of transcription factors to the promoter of target genes. TFOs include 
GA-rich or GT-rich DNA oligonucleotides and can bind to double-stranded DNA in the major 
groove. The TFO approach was used to prevent the binding of the transcription factors E2F 
and MAZ to the c-Myc gene's promoter and effectively decreased the c-Myc gene's 
transcription (McGuffie et al. 2000). 
Quadruplex-forming oligonucleotides are an alternative strategy to inhibit the c-Myc 
gene's transcription. The sense-strand up-stream of the c-Myc gene promoter contains a G rich 
region that can form a G-quadraplex structure when separated to a single strand. A 
Quadruplex-forming oligonucleotide could compete with the G-rich region in the c-Myc 
gene's promoter for binding to important factors, such as hnRNP K (heterogenous nuclear 
ribonucleoprotein K) and inhibit recruitment of the pol II complex to the promoter. The 
effective concentration of the oligonucleotide was in the nanomolar range (Hurley 2001). 
Anti-sense DNA and RNAi provided a possibility of inhibiting c-Myc gene's 
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expression at the mRNA level. Several groups used anti-sense DNA or RNAi with different 
cell lines to reduce the c-Myc gene's overexpression and block cell proliferation. For example, 
Leonetti and colleagues utilized phosphorothioate c-myc antisense oligodeoxynucleotides to 
treat transgenetic mouse with c-Myc overexpression and resulted in a prolonged decrease in 
c-Myc expression, reduced tumor growth and increased survival periods of treated animals 
(Leonetti et al. 2001). Brummelkamp et al. (2002) used short RNA interference to stably and 
specifically block the expression of the oncogenic K-RASV12 expression in human pancreatic 
carcinoma resulting in the loss of anchorage-independent growth and tumorigenicity 
(Brummelkamp et al. 2002). 
Another potential method to block the c-Myc transformation function in vivo is to 
interfere with the formation of the c-Myc:Max heterodimer. Berg et al. (2002) used the 
BR-HLH-LZ domain of c-Myc and Max to make the fusion proteins c-Myc-CFP and 
Max-YFP. When the two fusion protein dimerize, fluorescence energy transfer will occur 
between CFP and YFP. CFP and YFP are derivatives of the green fluorescent protein GFP. The 
authors screened around 10,000 peptido-mimetic substances and found four that could 
interfere with the dimerization of c-Myc and Max as indicated by the difference in 
fluorescence emission (Berg et al. 2002). 
In our project, we proposed to develop a bivalent aptamer that can bind to two sites on 
the c-Myc:Max protein: 1) the c-Myc:Max E box binding domain and 2) another site on the 
heterodimer in order to provide additional specificity and higher affinity for the c-Myc:Max 
target protein. 
An obvious advantage of an aptamer compared to other anti-cancer drugs is that it can 
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be developed into an allosteric aptamer or bivalent aptamer, this means two different aptamers 
recognizing different targets could be linked together and control each other’s function 
(allosteric) or function simultaneously. For example the c-Myc:Max aptamer could be linked 
to another aptamer that can specifically bind to an anti-cancer drug, such as Gleevec. If the 
aptamer was allosteric and only allowed Gleevec binding when it bound c-Myc:Max, the 
binding of the c-Myc:Max aptamer to c-Myc:Max would allow the anti-Gleevec aptamer to 
drive more Gleevec into the cells with c-Myc:Max overexpression, therefore increase the local 
concentration of the anti-cancer drug. 
If the two strategies above could be combined, it will be much more powerful than a 
single treatment. So the c-Myc oncogene had been regarded as a target of cancer therapy and 
recent published results have shown that different strategies can be used to inhibit the cellular 
effects of deregulated Myc gene expression. 
Aptamer 
Aptamers are single stranded DNA or RNA developed in vitro from a random pool to 
execute certain functions. Aptamers can tightly and specifically bind to their target molecules. 
The targets of aptamers range widely from small molecules, such as ATP, metal ions etc. to 
macromolecules, such as peptide, protein, even whole cells. 
The basic procedure for developing aptamers is termed SELEX (Systemic Evolution 
of ligands by Exponential Enrichment). SELEX starts with a large random single strand DNA 
or RNA pool including 1014 -1015 molecules; each molecule has a random region, which is 
usually from 30-40 nucleotide long (Ellington and Szostak 1990; Tuerk and Gold 1990). On 
the both sides of the random sequences there are fixed sequences for PCR primer annealing; 
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for RNA molecules the 5 prime includes the T7 promoter for T7 RNA polymerase binding. 
The critical step of SELEX is partition from those nonspecific binders of ssDNA or RNA 
molecules that can specifically bind to targets. Several methods can be used to realize the 
partition. Examples are nitrocellulose filter binding, EMSA, and affinity chromatography. The 
selected pool then can be amplified by PCR (polymerase chain reaction). When selecting from 
an RNA pool, it is necessary to synthesize a complementary DNA strand by reverse 
transcription and then do PCR to amplify. In order to develop new molecules low fidelity PCR 
is necessary to introduce some mutations in the selected population. A new single stranded 
library can be generated by separation of the double stranded DNA PCR product for DNA or 
by transcription for RNA molecules. The same selected procedure will be repeated until the 
binding efficiency is up to the expected percent (Jayasena 1999). 
One of the critical strategies of SELEX is to determine the ratio of target molecules to 
selected pool. Another concern during SELEX is to avoid accumulation of those molecules 
that can bind the support materials (such as filter or column) and related molecules or analogs 
of the true target. So sometimes negative selections against the support materials or related 
molecules are necessary. The strategy of negative selection is based on the high specificity of 
aptamers. It was reported that aptamers can discriminate subtle structural differences between 
the true target and other molecules that differ by features such as a methyl group (Haller and 
Sarnow 1997; Jenison et al. 1994) or hydroxyl group (Geiger et al. 1996; Sassanfar M 1993). 
The number of rounds of SELEX depends on the target property and selection pressure. 
Usually 8-15 cycles are required to reach binding efficiency saturation. After the binding 
efficiency is saturated, the “winner” molecules in the enriched library are cloned and 
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sequenced. Further analysis is necessary to identify the true aptamers. This includes sequence 
alignment, affinity analysis and determination of the shortest truncated sequence of aptamers 
etc. The Kds of aptamers to protein targets is usually range from pM to nM (Gold et al. 1995). 
Kds for other molecules range from nM to μM. For example, the Kd of theophylline is 
~0.1μM (Jenison et al. 1994) and of dopamine is ~2.8 μM (Mannironi et al. 1997). Generally 
the whole procedure including positive selection, negative selection, cloning and sequencing 
takes 2-3 months. 
Comparison of aptamer and antibody 
The use of antibodies for analysis began in the 1950s and was widely applied in the 
1970s. From then on antibodies have shown tremendous power in diagnostic applications 
based on molecular recognition. 
In the 1990s, the first experiment of SELEX (Systematic Evolution of Ligands by 
Exponential Enrichment) provided a method to develop a different class of molecule-single 
stranded DNA or RNA termed an aptamer, which could be selected in vitro and possess some 
properties and advantages that antibodies do not have. These include: 
A) Antibody identification begins with animals so it is limited to molecules that can be 
tolerated by animals. This limit can be overcome by the SELEX procedure of aptamer 
identification. Aptamers are developed in an in vitro environment instead of in in vivo 
conditions. So aptamer selection does not rely on animals or cultured cells. 
B) Because of being prepared using an in vivo system antibody preparation is 
restricted by parameters in vivo, such as pH, temperature, salt concentration etc. So the 
interaction of antibody and target occurs optimally under physiological conditions. While for 
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aptamer selection, people can change the selection conditions in vitro including pH, buffer 
components, temperature etc. depending on the diagnostic or imaging purposes. 
C) The properties of the antibody can vary from batch to batch because a different 
animal is used each time. Aptamer molecules that are synthesized by a chemical procedure in 
vitro can be reproduced with a high degree of accuracy. It is also very easy to purify DNA or 
RNA aptamer molecules in vitro condition without changing their properties. 
D) Stability is a big challenge for protein antibody storage. Proteins are very easily 
denatured when stored dilute and at low temperatures, or when heated. Aptamers can endure a 
wide range of temperatures and can very quickly renature (Jayasena 1999).   
Applications of Aptamers 
The high affinities and specificities of molecular binding and recognition of aptamers 
as well as the possibility for aptamers to be selected, designed and modified make the single 
stranded DNA or RNA molecules potential powerful tools in diagnostics and therapeutics.  
Diagnostics 
In the traditional two-antibody sandwich diagnostics protocol, a monoclonal antibody 
for the protein of interest is captured on a solid surface; the target protein is then incubated 
with the monoclonal antibody. In order to improve the signal-to-noise ratio, a second antibody 
is added to the detection system of the bound protein. The second antibody can be detected by 
a detection signal of enzyme, biotin, fluorophores or radioactive isotopes (Jayasena 1999). 
Since methods were developed for the in vitro development of aptamers, the new 
reagent gradually plays important roles in protein diagnostics assay. The following properties 
of aptamers suggest that aptamers could be a good substitute for an antibody. First, aptamers, 
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as single stranded DNA or RNA molecules, can be selected in vitro by the SELEX procedure 
from a random pool, which only requires separation of bound and unbound molecules and 
PCR amplification. With the construction of a robot that can execute SELEX, the procedure 
becomes automatic and efficient. Second, the method of photo-SELEX can lead to cross 
linking between the aptamers and their targets and does not affect the binding between them. 
So the binding ability and cross-linking ability are doubly advantageous for aptamers that can 
make them excellent reagents for diagnostics (Brody and Gold 2000; Brody 1999).  
A. Aptamer-based sensors 
Biosensors have been developed based on recognition between biomolecules, such as 
proteins and nucleic acids, which allow rapid and selective detection of targets through 
transducers. Aptamer-based biosensors have obvious advantages compared to protein-based 
immunosensors that make aptamers powerful tools in diagnostics. First, aptamers can be 
modified to be attached to a surface support; the interaction between biotin and straptavidin 
can be utilized to fix aptamers to a proper support or the aptamer can be modified by the 
addition of one of several chemical groups and then linked chemically to the support. The 
immobilized aptamer on a sensor surface can be regenerated to be functional for repeated uses. 
A second advantage of aptamers is their ability to be labeled with a wide range of reporter 
molecules that can report the binding reaction of aptamer and target (Jayasena 1999). 
In one application, an anti-thrombin DNA aptamer was used to selectively detect 
thrombin in solution by evanescent-wave-induced fluorescence anisotropy. This was the first 
attempt to develop an aptamer-based biosensor. The author labeled the 5 prime end of the 
DNA aptamer with FITC (fluorescein isothiocyanate) and covalently immobilized the 3 prime 
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end to a glass surface via a modified amine. It was found that the fluorescence anisotropy of 
the immobilized thrombin aptamer increased as a function of the thrombin concentration and 
that the Kd was 1.1μM, which is 10 times higher than that of the unlabeled thrombin aptamer. 
This biosensor had a very low detection limit for thrombin of as little as 0.7 amol in 140pL 
volume (Potyrailo et al. 1998). 
The same strategy was used with a fluorophore-labeled PDGF (Platelet-derived 
growth factor) aptamer to detect the PDGF target in real time and in homogeneous solution. 
Data showed that this method was selective and sensitive; it could detect PDGF in the 
subnanomolar range. The significance of this assay is that it is the first application of aptamers 
to detect the growth factor PDGF using fluorescence anisotropy measurements (Fang et al. 
2001). 
In another application, a RNA aptamer selected to specifically recognize the protein 
trans-activator of transcription (Tat) of HIV-1 was utilized as the bio-recognition element of a 
biosensor. The RNATAT aptamer showed 133 times higher binding affinity than the natural 
HIV-1 trans-activation response element (TAR) RNA. In this work, the RNA aptamer was 
immobilized on the sensor surface through the interaction between biotin molecules attached 
to the aptamers and streptavidin fixed on the sensor support. This assay could detect 0.65ppm 
(mg/L) of target protein. Results also demonstrated a high specificity of the RNA aptamer for 
the specific protein (Tat) compared with other proteins (Minunni et al. 2004). 
B. Aptamer in molecular beacons  
Molecular beacons are stem-loop structure probes. A fluorophore and a quencher are 
linked to each terminus of the stem. The stem structure brings the fluorophine and quencher 
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close together and the fluorescence is quenched by the fluorophore/quencher pair. When the 
loop portion of molecular beacon interacts with its complementary sequence, such as part of 
an aptamer molecule, it will open the hairpin structure of the molecule and drive the 
fluorophore away from the quencher, so the fluorescence is turned “on” (Li et al. 2002). 
In one model of the interaction between aptamer and molecular beacon, part of the 
aptamer sequences is complementary with the loop structure of molecular beacon only when 
the aptamer is free from its target protein; so when the target-free aptamer hybridizes with 
molecular beacon, the conformation of molecular beacon will be changed and the termini of 
the stem portion will be separated, which results in emission of fluorescence. However when 
the target protein of aptamer is present in the system it will bind to the aptamer and block the 
site required to interact with molecular beacon, so the fluorophore/quencher pair will not be 
separated and there will be no emission of fluorescence signal (Li et al. 2002). This strategy 
has been used to detect the existence of proteins in buffer and in plasma for which a 
high-affinity and specificity aptamer had been selected (Jayasena 1999). 
Another application related to aptamer and molecular beacon is a construction of the 
thrombin DNA aptamer beacon to detect the protein thrombin. In this design, the length of the 
core sequence of the thrombin aptamer was extended from a 15-mer to a 17-mer by adding a 
thymidine nucleotide at both ends of the aptamer; then a fluorophore and a quencher were 
separately conjugated to the 5' and 3' end of the 17mer to get the 
fluorophore-quencher-labeled molecular aptamer beacon (MAB). When the thrombin MAB is 
free from its thrombin target, it exists in equilibrium between a random coil structure and a 
compact quadruplex (including two G-quartets structure). Because in the absence of thrombin 
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some parts of the MABs are in the nonstructural random state, the 5' end conjugated 
fluorophore (6-FAM) will give very high fluorescent signal. When the thrombin target is 
present in the system, it will bind to MAB and shift the equilibrium to the quadruplex structure. 
This will drive the fluorophore and quencher at the ends of the MAB closer, resulting in 
quenching of the fluorescence signal. Similar to the previous sensor, this sensor utilized the 
signaling characteristics of the molecular beacon and the high specificity of target recognition 
of the aptamer to provide a powerful analysis method for real time detection of a protein in 
vitro (Li et al. 2002) . 
C. Microarray based on aptamers for protein analysis 
It is useful to study gene products at the protein level instead of the DNA or RNA level 
because regulation during translational and posttranslational modification is not accurately 
reflected in DNA or RNA levels. Using an aptamer array to understand proteomics has some 
advantages because of the following properties of aptamers: 1) Aptamers can be quickly 
obtained by chemical synthesis with high accuracy; 2) Aptamer molecules can be fixed in a 
specific location on a solid support at the required density to make DNA microarrays; 3) UV 
cross-linking can generate irreversible links between aptamers and target proteins, which 
stabilize the specificity provided by affinity; 4) The range of targets for aptamers is wide, 
ranging from ion, small organism to peptides, proteins, viruses even tissues (Jayasena 1999). 
 Microarrays based on aptamers can be used as robust tools to analyze protein 
expression and can provide an important technology for disease diagnostics and development 
of new therapeutics. Collett and colleagues described a method of producing aptamer-based 
microarray slides. The authors used this aptamer chip array as a tool to characterize the 
  
20
 
binding properties of isolated aptamers to their corresponding target proteins. In this assay 
twelve selected chicken egg white lysozyme RNA aptamer candidates were biotinylated and 
printed on streptavidin slides. The slides were treated with decreasing concentrations of a 
fluorescent target protein. Binding of the aptamers to the target protein at each concentration 
could be detected by the fluorescence intensity of the spots on the slides when the slides were 
scanned. The detection limit was 1pg/ml. The aptamer-based microarrays provide a 
high-through put strategy to test the aptamer binding affinity (Collett et al. 2005). 
The same group also developed an aptamer-based microarray for detecting multiple 
protein targets. For this assay the authors generated a multiplex aptamer microarray for four 
different aptamers and their individual target protein including anti-lysozyme RNA aptamer, 
anti-ricin RNA aptamer, anti-lgE DNA aptamer and anti-thrombin DNA aptamer. The 
detection limit for each protein target was 5pM for lysozyme, 0.5nM for ricin, 10 pM for lgE 
and 5nM for thrombin, respectively. Each RNA and DNA aptamer showed a specific response 
to their target protein and not others (Eun Jeong Cho 2006). 
D. Design and application of allosteric nucleic acids based on aptamers 
An allosteric effect results when an allosteric regulator binds to a different site than the 
active site, and thereby induces a structural rearrangement of the molecule that influences the 
activity of the active site. Based on the concept of allosteric mechanisms several kinds of 
aptamer-based allosteric nucleic acids were designed. The first one is an allosteric ATP 
aptamer, which is based on the TRAP (“targeted reversible attenuated probe”) design. In this, 
the DNA sequence includes an ATP-DNA aptamer followed by an antisense sequence and an 
attenuator segment. In the absence of regulatory nucleic acid (reg NA), which is 
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complementary to the antisense sequence, the ATP aptamer part is attenuated by the attenuator 
therefore unable to bind to its target. When it is present, the reg NA will hybridize with the 
antisense sequence and separate the attenuator from the aptamer. The released aptamer can 
bind to its target. So in the TRAP model, the aptamer activity is regulated by hybridization 
between antisense and reg NA and the antisense sequence and aptamer part play roles of 
recognizing and signaling (Cong and Nilsen-Hamilton 2005). 
A similar design was also used in allosteric ribozyme. Data showed that the activity of 
hammerhead ribozyme could be increased by around 250 fold in the presence of regulatory 
sequences (Burke et al. 2002). 
CLAMP (cis-linked aptamers for medical and microanalytical procedures) is another 
design based on an allosteric mechanism. The allosteric CLAMP includes two cis-linked 
aptamers; the binding of target to one of the aptamers can regulate the activity of the other one. 
The advantage of the CLAMP structure is allowing the regulator or the target to be any kind of 
molecule as long as the proper aptamer can be obtained. A good example of CLAMP is 
currently under development. It consists of an ATP aptamer and a neomycin aptamer in one 
sequence. The binding of neomycin to neomycin aptamer increases binding of the ATP 
aptamer to ATP (Stodola 2003).  
Another allosteric aptamer design shares some similarity to the CLAMP. In this 
approach, an allosteric RNA aptamer can bind RVV-X (Russell’s viper venom factor X 
activator) and VEGF165 (human vascular endothelial growth factor). RVV-X has an 
enzymatic activity to trigger the reaction of coagulation cascade of blood components that 
could be used as a detectable signal. When VEGF165 is absent, the RNA aptamer has high 
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affinity for RVV-X and blocks its enzymatic activity, so no signal can be detected. The 
inhibitory effect is reversed by binding of the RNA aptamer to the effector 
molecule-VEGF165. Thus, the VEGF165 functions as a controller for the on/off switch of 
RVV-X enzymatic activity. The potential mechanism behind the effect is when the domain on 
the allosteric RNA aptamer which binds to VEGF165 is occupied by the effector; the domain 
for binding RVV-X on the aptamer is changed somehow, so the binding affinity of RVV-X is 
decreased. The difference between this allosteric aptamer design and CLAMP is the binding 
of one molecule to the aptamer decreases instead of increasing the binding of the other 
molecule (Chelyapov 2006). 
Based on the previous studies, RNA and DNA molecules can be designed to make 
functions as molecular switches in the presence of specific target molecule. Compared to 
DNA, RNA molecules have more flexibility to form proper structures needed for binding 
different targets. Breaker et al. (2002) first discovered and discussed the strategy of 
“riboswitch”. Three general strategies can be used to create engineered riboswitch: rational 
design, in vitro selection (SELEX) and combined design (rational design and SELEX). One 
example is the construction of an ATP-dependent RNA riboswitch. The approach was 
achieved by linking a hammerhead ribozyme domain to an RNA domain that can bind ATP. 
The ATP binding could create corresponding changes in structure in the catalytic domain of 
the ribozyme and so it could play roles in catalytic reaction (Breaker 2002). Interestingly, 
people also found natural versions of “riboswitch” in vivo. In structure, two allosteric 
glycine-binding RNA subunits are arranged in tandem. The binding of a glycine molecule to 
subunit I triggered the structure changes of RNA subunit II and helped the second subunit to 
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bind to glycine. The function of the riboswitch in vivo is to regulate expression of a gene 
related to glycine dependent energy consumption (Famulok 2004). 
Therapeutics  
The therapeutic function of an aptamer is based on the aptamer’s ability to directly 
inhibit its target molecule's function by folding into a proper 3-dimentional structure. Thus, 
the aptamer can specifically and tightly bind to the target with high affinity (Rebekah 2000). 
At the beginning of exploration of aptamer function as therapeutic reagent, the Tat 
protein was regarded as the target molecule to inhibit because it is responsible for HIV-1 RNA 
transcription through its direct interaction with TAR RNA (HIV trans-activation response 
element) (Minunni et al. 2004; Rebekah 2000). A “decoy” RNA aptamer was developed that 
could bind to Tat protein and inhibit HIV RNA transcription. This RNA aptamer was also 
proved to be functional in vivo. This significant study opened the way for an RNA molecule 
(and later single stranded DNA) to be utilized as a therapeutic reagent by its ability to 
specifically bind target proteins and inhibit their functions. 
Platelet-derived growth factor (PDGF) stimulates mesangial cell proliferation and cell 
matrix accumulation, which leads to cardiovascular diseases. Floege et al., (1999) utilized a 
nuclease-resistant and high-affinity DNA aptamer as an antagonist to PDGF and dramatically 
suppressed PDGF-induced cell proliferation. The high affinity and specificity of the DNA 
aptamer was reflected in the fact that, at the concentration of 1μg/ml, the anti-PDGF aptamer 
completely blocked rat mesangial cell growth and proliferation induced by PDGF but not by 
other growth factors, such as EGF or FGF. The Kd for the PDGF aptamer is around 0.1 nM 
(Floege et al. 1999). 
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Receptor tyrosine kinases (RTKs) are transmembrane proteins that initiate several 
important signaling pathways that regulate cell growth and differentiation in a variety of 
cancers. So RTKs were regarded as important targets for cancer diagnostics and therapeutics. 
Nuclease-resistant RNA aptamers that can specifically recognize the human RET (rearranged 
during transfection) RTK were isolated. The authors utilized RET RTK-expressing cells as the 
target during SELEX. The isolated RNA aptamer blocked RET-dependent signaling and 
related down stream molecular events and specifically bound its target. The Kd of the aptamer 
is 30-70 nM (Cerchia et al. 2005). 
The Raf-1 protein is another good therapeutic target for an aptamer. As a 
serine/threonine kinase in the cytoplasm, Raf plays important roles in transmitting signals of 
cell proliferation and development from plasma membrane and nucleus. Even though the 
molecular mechanism of signal transmission involving Raf-1 is not completely clear, it was 
known that the functional Raf-1 protein activity is tightly regulated by its interaction with Ras, 
which belongs to GTPases. The critical region of Raf-1 for its association with Ras is in 
51-131 amino acid, which is named Ras-binding domain (RBD). The authors isolated and 
characterized RNA aptamers which can specifically recognize Raf-1 RBD (the Kd is 
152±23nM) and can efficiently interfere with the interaction between Raf-1 and Ras, thus the 
isolated anti-Raf-1 RNA aptamer could be used as a tool to regulate Raf-1 involved signal 
transmission pathway and as a potential candidate of Raf-1 related cancer therapy (Kimoto et 
al. 2002). 
Several important issues needed to be considered for aptamers to be transformed from 
specific protein binders into potential therapeutic molecules in vivo. Generally, the size of the 
  
25
 
aptamer should be shortened to 40 nucleotides or less from the original length of around 
80-100 to get a minimum-sized aptamer with high specificity and affinity to target molecules. 
Also stability and systemic clearance of aptamer are two critical points for molecules to be 
effective in vivo. For RNA aptamers, the stability can be increased by selecting modified 
aptamers using 2'-amino or 2'-fluoro nucleotides to substitute for ribonucleotides. To avoid 
rapid systemic clearance, the small aptamers with molecular weight from 8,250 to 13,000 kd 
can be conjugated by polyethylene glycol (PEG) or attached to a liposome to increase 
molecular size (Rebekah 2000). 
VEGF (vascular endothelial growth factor) is a growth factor that is tightly correlated 
with psoriasis, macular degeneration and tumor proliferation. Development of a reagent that 
can limit or inhibit VEGF function in vivo could provide a method to effectively cure 
VEGF-related disease. A 2'-fluoropyrimidine RNA aptamer NX1838 conjugated with PEG 
was selected in 1999. This RNA aptamer can specifically bind to VEGF165 and block some 
VEGF 165-mediated cellular events, such as calcium mobilization, signal transduction and 
cellular proliferation. NX1838 was the first aptamer-based therapeutic molecule approved for 
use in the human (Bell et al. 1999). This aptamer is now in clinical use under the name of 
pegaptanib or macugen (Ng and Adamis 2006; Tobin 2006). 
A new potential way of aptamer application in therapeutics was generated for 
controlling gene expression via interaction between RNA aptamer and specific target 
molecules. In the mechanism of eukaryotic translation, a critical step in translational initiation 
is ribosome-mRNA interaction and 5'-3' scanning of ribosome from 5'-m7G cap to the start 
codon. Because an aptamer can be isolated to specifically bind to its target, it was tested that 
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whether a complex of aptamer-target in the 5' UTR (5' untranslated region) can repress gene 
translation by blocking ribosome scanning or by the interaction of ribosome and mRNA. This 
strategy was utilized in Chinese hamster ovary (CHO) host cells. The authors constructed a 
mammalian β-galactosidase expression vector with a copy of Hoechst dye 33258 aptamer in 
the gene’s 5'-UTR and a control vector without the aptamer. The constructed 
aptamer-containing or control plasmids were separately transfected into CHO host cells 
together with a luciferase reporter gene as an internal control. The results showed that when 
the target drug hoechst dye 33258 was absent, the expression level of β-galactosidase was 
similar for the aptamer containing expression vector and control vector, also expression of the 
luciferase internal control gene was not affected; but when the dye 33258 was present, the 
expression level of β-galactosidase from the expression plasmids that included either the H10 
or H19 Hoechst aptamers in the 5' UTR was dramatically lowered by more than 90% 
compared with that of control plasmid without H10 or H19 aptamers in 5' UTR. Again 
luciferase expression was the same for all plasmid constructs (Werstuck and Green 1998). 
This strategy developed a translational switch by inserting an isolated aptamer sequence in the 
5' UTR of a gene of interest to regulate translation by adding the specific target molecules into 
the in vivo system. 
Grate et al., (2001) showed the same strategy could work in the yeast strain S. 
cerevisiae. The authors targeted cyclin B2 (CLB2) gene as the gene of interest. CLB2 controls 
cell cycle transition from the G2 phase to mitosis in budding yeast cells. A malachite green 
aptamer sequence was inserted immediately upstream of the start codon of CLB2 gene. It was 
shown that the expression level of CLB2 was depended on the presence or absence of TMR 
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(tetramethylrosamine), a malachite green analog that can bind to the malachite green aptamer 
tightly (Kd ~40nM). Western blot analysis showed that 1μM TMR lead to a more than10 fold 
decrease of CLB2 protein expression, while the normal yeast strains without MG aptamer 
insertion in clb2 gene showed no difference before and after adding TMR. RT PCR and 
Western blot showed that the blocking effect of TMR on the expression level of CLB2 by the 
presence of the MG aptamer in the CLB2 gene did not occur at the transcriptional but at the 
translational level. 1-D NMR further demonstrated that the TMR ligand binding to the MG 
aptamer drove the secondary structure of the MG aptamer in the 5' UTR from a less stable 
state to a more stable state. This stable MG aptamer structure can inhibit movement of the 
ribosome along the mRNA and inhibit translation of the mRNA (Grate and Wilson 2001). 
These results showed that the binding of a small ligand to an aptamer in the 5'UTR could 
induce secondary structure conformational changes that could decrease the translational 
initiation rate. A strategy based on aptamer-target binding in the 5' UTRs of gene transcripts of 
interest in vivo could inhibit translation of the message and thereby provide a new way of 
using aptamers for therapeutic applications to inhibit specific disease-related gene expression.  
SELEX 
The Establishment of the SELEX Method 
The first SELEX experiments were executed in Dr. Larry Gold’s lab in University of 
Colorado in 1990 (Ellington and Szostak 1990; Tuerk and Gold 1990). When the SELEX 
strategy was designed, the researchers in Gold’s lab worked on the translational regulation in 
T4 bacteriophage-infected E.coli. They found that genes 32 and 43 encode DNA binding 
proteins, and the protein products can negatively regulate their own expression by binding to 
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the translational initiation region of their corresponding mRNA. 
It was known that the mRNA target for T4 DNA polymerase (the gene 43 encoded 
protein) includes a loop-stem (or hairpin) structure upstream of the AUG. People who were 
interested in the self translational repression of bacteriophage T4 DNA polymerase tried to 
figure out the sequences required for the protein-mRNA interactions by generating some 
mutations in the loop range of the mRNA. They thought a random pool of mRNA sequence 
could be an ideal source to provide the desired sequences. They started with a library 
containing 1014 to 1015 different mRNA molecules including 8 random sequences of each 
molecule to incubate with the T4 DNA polymerase target in 3 different ratios of RNA to 
protein (10:1, 100:1 and 1000:1). After repeated binding, separation, replication (RT PCR and 
PCR) and in vitro transcription, the aptamer candidate molecules were cloned and sequenced. 
The data showed that the SELEX experiment yielded two different groups of sequences in the 
loop region. One was the same as the wild type binding sequence; the other one included four 
mutations, and was named the “quadruple mutant”. The two groups of aptamers had similar 
Kd (~4.8x10-9 M). Based on these data, the researchers further imagined that single-stranded 
DNA or RNA aptamers could be developed for many kinds of molecular targets (Gold et al. 
1997; Tuerk and Gold 1990). 
At the same time when Dr. Gold’s lab isolated the RNA aptamer of T4 DNA 
polymerase, Dr. Szostak’s lab also began to develop RNA molecules that can bind to small 
molecules of several dyes via in vitro selection. The starting pool they used included roughly 
1013 different RNA molecules and 100 random oligonucleotides for each molecule. They used 
affinity column chromatography to separate the specific binders and nonbinders. The Kds of 
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aptamers specific for different target dyes ranged from 100 μM to 600 μM (Ellington and 
Szostak 1990). 
The isolation of functional RNA molecules that can specifically bind to given targets 
suggested that a similar method could be used to provide single stranded DNA molecules that 
can properly fold into certain structures and specifically bind to corresponding targets. 
Ellington and Szostak (1992) used a single stranded DNA pool from which to select aptamers 
that bind several dye molecules including Cibacon blue, reactive green and reactive blue. 
They found that the DNA-target interactions are both sequence and target-specific. The Kds 
were 30 to 50 μM (Ellington and Szostak 1992). From their experimental data, single-stranded 
DNA could be regarded as alternative potential diagnostic and pharmaceutical reagents 
(Ellington and Szostak 1992; Klug 1994) 
Development of SELEX  
Genomic SELEX 
As people found more and more proteins playing roles in regulating gene expression 
through binding specific target DNA or RNA sequences, a new method derived from SELEX, 
which is termed “Genomic SELEX”, was developed. Genomic SELEX utilized the whole 
genomic sequences of a certain organism as the original pool instead of random sequences to 
isolate the specific and tight binding oligonucleotides for a target protein. To some extent, 
genomic SELEX could be thought a “global search” method to predict the potential networks 
of interaction between protein and nucleic acid in vivo. 
How to establish a high quality starting genomic library that can represent the whole 
genome of a certain organism is a critical step for genomic SELEX. Singer et al., (1997) 
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reported an approach starting with random priming on sheared denaturing genomic DNA to 
construct the original pool. First the authors designed a 5 prime primer (A ran) and a 3 prime 
primer (B ran), each including a fixed sequence at 5 prime and a nine random sequence at 3 
prime individually. They chose denatured human, yeast and E.Coli genome DNA libraries as 
the templates to be annealed to the 3 prime primer (B ran), which is expected to randomly 
distribute through the genomic DNA; then Klenow was used to perform the extension reaction. 
The 5’ primer (A ran) then was added to the system and the extended product above was used 
as a new template to anneal and extend again. The extended products should include various 
fragments of different lengths. These products were then resolved through a denaturing gel 
and purified via electro-elution. The purified eluted products were annealed to new primers, 
primer A with same fixed sequence as primer “A ran” but also with a T7 promoter at the 5 
prime end, and primer B containing the same fixed sequences as primer “B ran” for 
amplification. So the resulting amplified double stranded products should contain inserts 
consisting of genomic DNA sequences of different lengths surrounded by 5 prime and 3 prime 
sequences. The authors also tested the distribution of the end-points (an end-point means the 
last genomic nucleotide in each fragment in the library) of a certain region of genomic inserts 
in the library and the sequence accuracy of the library. Data showed that the library “contains 
overlapping inserts starting at most of the positions within the genome”. In the tested genomic 
regions, the longest distance with no end-point was only 9 nucleotides long. The sequence 
fidelity of the tested library inserts was high compared to the published genomic sequence 
(Gold et al. 1997; Singer et al. 1997). 
Besides random priming, several other methods were developed to construct genomic 
  
31
 
libraries, such as mechanical fragmentation and blunt-end ligation (Sompayrac and Danna 
1990). and restriction digestion and ligation (Kinzler and Vogelstein 1989). 
Very similar to SELEX of random sequences that uses oligonucleotides to generate a 
diverse library, genomic SELEX generates a diverse library of sequences from genomic DNA. 
Both procedures involve separation of specific and nonspecific binders and non-bound 
molecules, amplification of the specific binding species, cloning and sequencing of the 
“winner” aptamer candidates. 
In the very early stage of genomic SELEX application, a RNA library derived from 
E.coli by random primer extension was used as the original pool and the MS2 coat protein was 
chosen as the target molecule because the in vivo E.coli RNA sequence required to bind MS2 
was already known. Results showed that the fixed region in the primer sequences used to 
amplify the library participated in forming binding site of the selected aptamers. Also, when 
the library was constructed, the two primers included nine random sequences that may 
misanneal to the template, thus provided some extra mutations to the library. The mutated 
region also could be part of the binding sites of the target protein. 
In order to avoid these unwanted situations, researchers replaced the fixed and random 
sequences in the primers with new fixed sequences selected via computer program (STOGEN) 
design, so the new fixed sequence should form none or very little secondary structure on their 
own or with genomic sequence region in the library. These changes were made so as to 
decrease the possibility that the primers would participate in formation of potential binding 
sites for target protein. 
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Auto SELEX 
The normal SELEX procedure is repetitive and time consuming. If an average of 12 
rounds of selection is required to select an aptamer, it will take around two months. 
Sometimes for some steps, such as PCR and PCR product purification of selection pool need 
to be repeated. Thus the whole procedure of SELEX will take a longer time than generally 
expect (Cox and Ellington 2001; Cox et al. 1998). 
Cox et al., (2002) automated the in vitro selection procedure using a specially modified 
Beckman Biomek 2000 robot. They integrated a thermal cycler for selected pool amplification, 
a magnetic bead separator for separation of target-nucleic acid complexes and free nucleic 
acid, an enzyme cooler and pipetting tools into the Biomek system, which are required for 
auto-SELEX. 
In the first attempt of automated selection, oligo (dT)25 was attached to Dynabeads as a 
target to test the feasibility and efficiency of the automated system. A RNA pool including 30 
random sequences was used as the starting pool. The time spent to complete one round of 
auto-SELEX including mixing of pool and target, elution of bound RNA sequences, RT-PCR 
and in vitro transcription was only 212 minutes, which was impressive compared to the days 
or a week of manual SELEX. The sequence data showed that all cloned sequence included 
continuous poly A, which was expected for oligonucleotide (dT)25 target’s binding sites. This 
successful attempt provided high possibilities for other targets, such as protein, to be used in 
the auto-selection procedure (Cox et al. 1998). 
The researchers then utilized the automated aptamer selection method to develop an 
anti-lysozyme aptamer. In this selection procedure, filtration was used to separate the specific 
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binders and the unbound nuclei acids. Target lysozyme was biotinylated and fixed on 
streptavidin beads, the mixture of selected pool and target-bound beads was then filtered 
through a low protein-binding membrane. In this experiment, selection was repeated for 12 
rounds; the whole procedure took around 12 hours. Sequence comparison results showed that 
six binding species were developed from the original pool. One of the binding species 
constituted 61% of the total chosen colonies (22/33). The dissociation constant of the highest 
affinity aptamer was 31nM. The automated workstation can simultaneously deal with eight 
selections and can finish 12 rounds of selection in two days. The same auto-SELEX strategy 
were utilized to isolate aptamers of some other protein targets including human U1A (a 
component of the nuclear splicesome), MEK1 (a human MAP kinase) etc. Generally the Kd 
value is from pico molar to mid-nanomolar (Cox et al. 2002). 
Capillary SELEX 
The procedures of SELEX have been gradually improved with time. For affinity 
column chromatography, the conventional method of capturing potential aptamers in SELEX, 
a certain target molecule needed to be linked to a matrix support, such as agarose; some 
potential binding sites of the target may be blocked by linking to the matrix, which could 
decrease the binding efficiency of SELEX. Another commonly used SELEX method, the filter 
assay could avoid the problem above because the binding between oligonucleotides and target 
occurs in free solution without linking to a support material. But sometimes it could provide a 
high binding background of oligonucleotides. Considering the shortcomings of conventional 
SELEX methods, Mendonsa and Bowser (2004) at the University of Minnesota utilized 
capillary electrophoresis (CE) and showed it could work well in SELEX for different targets 
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(Mendonsa and Bowser 2004). CE showed several important advantages compared to affinity 
column and filtration as a method of capturing the target-aptamer complex. First, with CE, 
single-stranded DNA or RNA molecules bind to their corresponding targets in solution instead 
of the target being attached to a support matrix. This avoids the necessity to block binding 
sites. Second, oligonucleotide molecules specifically bound to targets can be separated from 
those nonbinding oligonucleotides according to size and charge differences. Thus washing 
steps are unnecessary. Third, the whole procedure of CE SELEX only take 2-4 days instead of 
the weeks to months that it takes for other SELEX methods. 
The researchers first used human IgE as the binding target. After two rounds of 
selection using CE, they had around 95% binding but they didn’t do negative selection. After 
cloning and sequencing the winning sequences, they showed that the average Kd value was 
less than 100 μM, and the best one was 27±8 nM (Mendonsa and Bowser 2004). 
The same group also determined the minimum size of target molecules that could be 
used in CE SELEX. They chose NPY (neuropeptide Y), a 36-amino acid peptide, which is 
smaller than a 80-mer single stranded DNA. Results showed that the Kd of the single stranded 
DNA aptamer of NPY isolated via CE-SELEX was in the high nanomolar range after four 
rounds of selection. The specificity of the single stranded DNA aptamer to NPY was also 
tested and it showed 42-fold selectivity for NPY compared to the human pancreative 
polypeptide. So the data showed that even a molecule that is as small as NPY could be used as 
a target of CE-SELEX. The strategy of SELEX using CE could be considered for selection of 
other single stranded DNA or RNA aptamers (Mendonsa and Bowser 2005). 
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Photo SELEX 
Photochemical SELEX (PhotoSELEX) is the procedure through which the aptamers 
are isolated through a covalent, in vitro selection method (Golden et al. 2000). The 
establishment of photo SELEX is based on the development of photoaptamers, which are 
derived from aptamers by replacing the thymidine (T) with a brominated deoxyuridine (BrdU). 
Photoaptamers possess the ability to crosslink to specific sites on target proteins by forming 
covalent bonds when electronically excited by long wave UV light (Dom Zichi 2002). The 
binding ability and crosslinkability is based on recognizing the shape and charge distribution 
of the targets and make photoaptamers an excellent reagent for diagnostics (Brody and Gold 
2000). The development of multiplexed photoaptamer-based arrays allow multiple proteins of 
interest to be simultaneously measured and the relative data showed that a 17-plex 
photoaptamer array could achieve the detection of target proteins including interleukin-16, 
vascular endothelial growth factor at the 10 fM level (Bock et al. 2004). 
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MATERIALS AND METHODS 
Plasmids and oligonucleotides 
Express vector pRSET-6His-c-Myc (human) and pET15b(+)-6His-Max (human) were 
donated by Dr. Ernest Martinez; the following oligonucleotides were synthesized by 
Integrated DNA Technologies (Coralville, IA): Oligonucleotide pool 2001: 5'-GAG AGA 
GGT AGG AAT GGC ACG TGN (NNN)13 NNG AAC ACA GCC TTG CCT GGA AT-3'; 
oligo 1201: 5'-Bio/ATT CCA GGC AAG GCT GTG TTC-3'; oligo 1931 5'-GAG AGA GGT 
AGG AAT GGC ACG TG-3'; oligo W-1218: 5'-GAG AGA GGT AGG AAT GGC ACG TGA 
TCG TGG TGG GGG AGG AGG GGA GCC AAG TTC GGT GAA TGA GGA ACA CAG 
CCT TGC GTG GAA T-3'; oligo W-1223: 5'- GAG AGA GGT AGG AAT GGC ACG TGT 
GGG GGG ATA CCC CAG TCG TGC AGC ACT AGG TAC GTT GAG TCG AAC ACA 
GCC TTG CCT GGA AT-3'; oligo W-1234: 5'-GAG AGA GGT AGG AAT GGC ACG TGT 
ACG TTG GGT GTC AGT GGT CTC AGT GCG  GTG GTT CTG GGG TGA ACA CAG 
CCT TGC CTG GAA T-3'; oligo T1-1218: 5'-GGG GAG GAG GGG AGC CAA GTT CGG 
TGA ATG AGG AAC ACA GCC TTG CC-3'; oligo T1-1223: 5'-GCA CGT GTG GGG GGA 
TAC CCC ATG CGT GC-3'; oligo T2-1218: 5'-CAC GTG ATC GTG GTG GGG GAG GAG 
GGG AGC CAA GTT CGG TGA ATG AG-3'; oligo T2-1223: 5'-CAC GTG TGG GGG GAT 
ACC CCA GTC GTG CAG CAC TAG GTA CGT TGA GTC-3'; oligo T2-1234: 5'-CAC GTG 
TAC GTT GGG TGT CAG TGG TCT CAG TGC GGT GGT TCT GGG GT-3'; the following 
oligonucleotides were synthesized from DNA facility of Iowa State University  oligo E box: 
5'-GCT CAG GGA CCA CGT GGT CGG GGA TC-3'; oligo 154: 5'-CGG GGA GAC AAC 
GAC GGC GGT GG-3'; oligo 155: 5'-CGG ATT CTC TGC TCT CCT CG-3'; oligo 156 5'- 
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GGA GCG CCA GAG GAG GAA CG-3'; oligo 180: 5'-CTG CGA CGA GGA GGA GAA 
C-3'; oligo 191: 5'-CCA CAC ACA CCA GCA AGA-3'; oligo T7-1: 5'-AAT ACG ACT CAC 
TAT AG-3'; oligo PETREV: 5'-GCT AGT TAT TGC TCA GCG G-3'. 
Materials and Equipment 
BL21-codonPlus (DE3)-RP competent cells for expression human c-Myc and BL21 
(DE3) pLysS Competent cells for expression human Max were purchased from Stratagene (La 
Jolla, CA); BD TALON Metal Affinity Resins for protein purification was purchased from BD 
Biosciences; the SELEX buffer was 13.5 mM NaCl, 100 mM KCl, 0.22 mM Na2HPO4, 5 mM 
MgSO4, 120 nM CaCl2, 5 mM MgCl2, 0.05% NP40, 20 mM HEPES, pH7.25. The buffers for 
dialysis and storage of protein included BC500 and BC100. BC500 contains 20 mM Tris-HCl 
pH7.9, 20% glycerol, 500 mM KCl, 0.05% NP40, and 10 mM 2-mercaptoethanol; BC100 
contains the same components as BC500 except 100 mM KCl. The Coomassie (Bradford) 
Protein Assay Kit was ordered from PIERCE (Rockford, IL). The ECL Western blotting 
detection reagents and analysis system were purchased from Amersham Biosciences 
(Piscataway, NJ). The mixed cellulose nitrate and cellulose acetate membrane filters 
0.22um/25mm GSTF 025 00 for SELEX were from Millipore (Bedford, MA). The 
Dynabeads-280 Streptavidin-linked beads were from Dynal Biotech, the TOPO TA cloning kit 
was from Invitrogen (Carlsbad, CA), the γ32P-ATP was from ICN (Costa Mesa, CA), the 
Micro Bio-Spin 30 chromatography columns for purifying oligonucleotides were from 
BD-BioRad (Hercules, CA), and the phosphorimager screen for exposure of EMSA gels was 
from Amersham Biosciences (Piscataway, NJ). Equipment used included a Typoon 8600 
variable mode imager from Amersham Pharmacia Biotech (Piscataway, NJ), an air-driven 
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ultracentrifuge from Beckman (Fullerton, CA) and a minicycler PCR machine from MJ 
Research (Waltham, MA). The software used for predicting ssDNA structure was Mfold 
(Zuker 2003). 
Checking cDNA sequences of human c-Myc and Max cloned in expression vectors 
Primers T7-1, 154, 155, 156 and 180 were used for sequencing the human c-Myc 
cDNA and primers T7-1, PETREV, and 191 were used for sequencing the human Max cDNA 
by the DNA facility of Iowa State University. 
Protein Expression and Purification 
Expression of recombinant human c-Myc and Max protein in E.coli 
The pET15b(+)-6His-Max plasmid was transfected into BL21 (DE3) pLysS competent 
cells (Stratagene). The pRSET-6His-Myc was transfected into BL21-codonPlus (DE3)-RP 
competent cells (Stratagene). Transformed bacteria were cultured in 500 ml LB culture media 
including 100μg/ml ampicillin at 37EC for 16 hours. Five ml of the above culture media was 
transferred to 1L fresh LB media including 100μg/ml ampicillin and the culture shaken at 225 
rpm at 30EC until the cell density had reached 0.3-0.4 OD600nm. IPTG (0.5mM) was added and 
shaking was continued under the same conditions for another 3 hours. Bacterial pellets were 
collected by centrifugation. The bacteria pellets were stored at -80EC or protein purification 
was continued. 
Purification of recombinant human Max protein 
The bacterial pellet was resuspended in 15ml cold lyses buffer (20 mM Hepes, pH7.9, 
500 mM NaCl, 10% glycerol, 0.1% NP 40, 10 mM 2-mercaptoethanol, 1 mM PMSF) and 
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sonicated on ice. The lysate was centrifuged and the supernatant containing soluble 6His-Max 
protein was collected and incubated at 4EC for 4 hours with rotation with 1ml TALON Metal 
Affinity Resins containing 5 mM imidazole. The resin was washed 3 times with 5ml cold 
lysed buffer containing 5 mM imidazole then 3 times with 1ml buffer BC500 containing with 
5mM imidazole, followed by once with BC100 containing 15 mM imidazole then once with 
BC100 containing 30mM imidazole. Recombinant 6His-Max protein was eluted from the 
TALON resin with 300 mM imidazole in BC100. All the steps were performed at 4EC. The 
concentration of purified protein was determined using the Coomassie (Bradford) Protein 
Assay Kit. The size of the protein was determined by SDS-PAGE (sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis) with Coomassie blue staining as well as Western 
blotting.  
Purification of recombinant human c-Myc protein 
The bacterial pellet was suspended with 15 ml cold lysed buffer (20 mM Hepes, pH7.9, 
500 mM NaCl, 10% glycerol, 0.1% NP 40, 10 mM 2-mercaptoethanol, 1 mM PMSF) and 
sonicated on ice. The lysate was centrifuged, and then the insoluble 6His-cMyc in the pellet 
was resuspended in 10 ml E-buffer (50 mM Hepes, pH7.9, 5% glycerol, 0.5 mM 
2-mercaptoethanol, 0.05% Na-deoxycholate, and 1% NP40) and homogenized. The inclusion 
bodies were separated by centrifugation; the pellet that contained the insoluble 6-His-cMyc 
was suspended with S-buffer (10 mM Hepes, pH7.9, 6 M guanidine-HCl, and 5 mM 
2-mercaptoethanol) and shaken overnight at 4EC. The mixture was separated by 
centrifugation to remove aggregates then the supernatant containing denatured 6His-cMyc 
was brought to 5 mM imidazole and incubated with 1ml TALON Metal Affinity Resin for 2 
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hours at 4EC. The resin was washed 3 times with S-buffer containing 5 mM imidazole, 3 times 
with 1ml BC500 containing 7M urea and 5mM imidazole, once with BC100 containing 7M 
urea and 15mM imidazole then once with BC100 containing 7 M urea and 30 mM imidazole. 
The recombinant 6-His-cMyc was eluted with 1ml BC100 containing 300 mM imidazole and 
7 M urea. The concentration of purified protein was determined using the Coomassie 
(Bradford) Protein Assay. The size of the protein was determined by SDS-PAGE and 
Coomassie blue staining as well as by Western blot. 
Reconstitution of the c-Myc:Max complex 
To obtain the c-Myc-Max heterodimer, c-Myc and Max were refolded together by 
step-wise dialysis starting with a molar ratio of 3:1. One mg c-Myc and 100 μg Max were 
mixed in 1ml BC100 containing 7 M urea and incubated at 37EC for 30 min. The protein 
mixture was dialyzed in “Mini Dialysis Tubing” (MW cutoff: 3.5kDa) in 8 successive steps of 
2 hour each against BC500 containing 4 M urea, BC500 containing 2 M urea, BC500 
containing 1 M urea, BC500 containing 0.5 M urea, BC500, BC100 (for twice) and SELEX 
buffer. To remove aggregates formed during refolding, the preparation was then spun for 2h at 
103,000 x g (80,000 rpm) using an air-driven ultracentrifuge. The reconstituted heterodimer 
was stored at 4EC. 
EMSA (Electrophoretic Mobility-Shift Assay) 
End labeled E box probe  
One hundred pmol double-stranded E box was end labeled with γ32P using 20 μCi 
γ32P-ATP at 37EC for 2 hours. The labeled DNA probe was separated from the ATP and 
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phosphate using a micro Bio-Spin 30 chromatography column. The specific activity of the 
probe was determined by TCA precipitation. The concentration of DNA was determined using 
a Nano Drop NP-1000 spectrophotometer and stored at -20EC. 
EMSA  
The interaction between the c-Myc:Max heterodimer and the E box probe was 
performed in a 20 μl final volume containing 25 mM Tris-HCl pH 7.9, 15% glycerol, 100 mM 
KCl, 0.15 mM EDTA, 0.075% NP40, 7.5 mM 2-mercaptoethanol, 160 ng poly(dIdC):(dIdC), 
375 μg/ml BSA. The incubation period was 30 min at room temperature (~24EC). The binding 
activities were analyzed by running the samples through 6% native PAGE in 20 mM 
Tris-acetate, 0.5 mM EDTA, pH 7.9 at 150 V and 2 hours at 4EC. 
SELEX (Systematic Evolution of Ligands by Exponential Enrichment)  
Positive Selection against c-Myc:Max 
A 100-pmol single stranded DNA pool, including 42 random sequences, was end 
labeled as described previously. Certain amounts of c-Myc:Max protein and labeled ssDNA 
pool were incubated at ~24EC with constant rotation under SELEX buffer for 1 hour. The 
DNA-protein complexes were collected on a filter by loading the mixture of target protein and 
single-stranded DNA molecules on a membrane filter GSTF 02500 and filtering at a pressure 
of 125 mm Hg. Then the filter was washed 3 times with 1 ml of SELEX buffer. Protein bound 
DNAs were eluted with hot buffer containing 7M urea, 100 mM sodium citrate, 3 mM EDTA 
pH 9. The total cpm in the protein-bound pool was determined using Cerenkov radiation 
measured with a scintillation counter. The selected ssDNA pool was concentrated by 
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precipitation with 100% ethanol then amplified by PCR in which one primer was biotinylated.  
The PCR product and streptavidin beads were incubated at ~24oC for 30 min in B&W 
buffer (5 mM Tris-HCl pH7.5, 0.5 mM EDTA, 1 M NaCl) then the buffer was removed by 
removing the magnetic beads using magnetic separation. The beads were incubated in 1X SSC 
(0.15 M NaCl, 0.015 M NaCitrate pH 7.0) for 5 min at 95EC then the ssDNA eluted in this 
buffer was retrieved. 
Negative Selection against the membrane filter     
The ssDNA pool was end-labeled with γ-32P as described previously. The 32P-labeled 
selected ssDNA pool was loaded on a membrane filter GSTF 02500 and pulled through under 
a pressure of 125 mm Hg. The cpm (counts per minute) of the flow-through was determined 
by a scintillation counter and used to calculate the binding efficiency of the pool. The 
flow-through was collected and concentrated by precipitation with 100% ethanol. 
Negative Selection against human Max and the membrane filter 
The ssDNA pool from a positive selection was end labeled and incubated with a 
chosen ratio of human Max and ssDNA pool at ~24EC for 1 hour. The protein-ssDNA mixture 
was loaded onto membrane filter GSTF 025 00 and pulled through at the pressure of 125 mm 
Hg. The cpm of the flow-through was determined with a scintillation counter and used to 
calculate the binding efficiency and the flow-through was concentrated by precipitation with 
100% ethanol.  
The positive and negative selections were repeated for 13 rounds until the binding 
efficiency was up to ~80% of the total cpm. 
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Cloning of candidate aptamer molecules for sequencing 
After the binding efficiency reached 50% the PCR products were cloned into PCR 2.1 
TOPO TA plasmid and transformed into One Shot Top10 competent cells to produce clones 
with the plasmids that included the PCR product inserts. Fifty colonies were chosen for 
preparing plasmids and sequencing. 
Filter Assay to check the binding abilities of the cloned oligonucleotides   
The 50 sequenced oligonucleotides (including the E box and the random region but not 
the majority of the primer sequences) were synthesized and end labeled with γ-32P. The 
oligonucleotides were each incubated with c-Myc:Max at a molar ratio of 1:1 in SELEX 
buffer at ~24EC for 1hour, and then the binding efficiency of each oligonucleotide for 
c-Myc:Max was determined by filter assay using the same procedure described in “Positive 
Selection against c-Myc:Max”. 
EMSA to check the binding ability of the putative aptamers from SELEX to c-Myc:Max 
Five oligonucleotides were chosen from the results of the filter assay for which 
15-23% of the total cpm bound c-Myc-Max. The complete sequences of these 
oligonucleotides were determined and synthesized, and then their 2-dimensional structures 
were determined using Mfold. This analysis was used to establish truncated oligonucleotides 
that are likely to contain the aptamer sequence. EMSA was performed with each 
oligonucleotide including the complete sequences (including primer sequences) and truncated 
sequences. For each oligonucleotide BSA was substituted for c-Myc:Max as a control. In 
some studies, the 32P-labeled oligonucleotide was mixed with an unlabeled oligonucleotide 
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(such as the E-box) at ratios of labeled to unlabeled oligonucleotide of 1:50 and 1:100.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
45
 
RESULTS AND DISCUSSION 
Expression and Purification of full length of human 6His-tagged c-Myc and Max fusion 
proteins in E.coli 
The Max protein was expressed in the host cell line BL21(DE3) pLysS (Stratagene). 
The Myc protein includes 8% proline residues and its c-terminal contains around 14% 
arginine residues. A strong bias of codon usage for these two amino acids is known to exist 
between humans and bacteria. In order to avoid truncated or limited expression of the c-Myc 
protein in E.coli we chose BL21-CodonPlus (DE3)-RP as the host cells to express the Myc 
protein. This E.coli strain includes extra copies of genes encoding tRNAs that carry arg and 
pro and recognize the arginine codons “AGA/AGG” and the proline codon “CCC”, which are 
commonly used in human but not bacterial cells (Stratagene). 
Recombinant Max was soluble and could be accumulated without degradation in 
nondenaturing conditions by collecting several elution fractions from cobalt-affinity 
chromatography on “TALON” resin (Clontech). The c-Myc protein was insoluble and needed 
to be purified under denaturing conditions. The left panel of figure 2 shows the Coomassie 
blue staining of the c-Myc; the result showed that the majority of the elution fraction was the 
c-Myc. The right panel of figure 2 shows the Western blotting result using the primary mouse 
anti-his antibody and the secondary goat anti-mouse IgG-HRP antibody; the data showed that 
the c-Myc was successfully expressed and purified from the host cells. The apparent 
molecular weight of c-Myc was around 64Kd in 15% PAGE, which is as same as the 
published literature (Farina et al. 2004), but theoretically it should be 49 Kd. The 
inconsistence here could be explained that under SDS and heating conditions, the c-Myc 
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protein may not bind as much SDS as other proteins of the same length. 
Figure 3 showed that the Max was also successfully expressed and purified from host 
cells. The left panel in figure 3 shows the Coomassie blue staining of Max and the right one 
shows the Western blot result. The Western blot shows that there was some contamination in 
the elution fraction of the Max, but the major component was Max as shown by Coomassie 
blue staining. The contamination did not seem to affect the refolding of c-Myc:Max 
heterodimer as described below and shown in figure 4. 
Refolding and analysis of recombinant full length c-Myc:Max complex 
Previously, others have tried to prepare the Myc:Max heterodimer by separately 
isolating and refolding denatured recombinant Myc and Max, mixing them together, and 
heating at 37 oC or 42 oC to allow the Max homodimer to dissociate and the Myc:Max 
heterodimer to form (Kato et al. 1992). Using this protocol resulted in a very unstable 
Myc:Max heterodimer and required several micrograms of Myc protein to form the 
heterodimer (Kato et al. 1992; Reddy et al. 1992). In our experiment, we used a protocol of 
co-refolding full length of c-Myc and Max protein by slow stepwise dialysis as described 
previously (Farina et al. 2004). The molar ratio of c-Myc to Max used for refolding was 3:1. 
To prove that the c-Myc:Max complex properly refolded and was able to bind its target DNA 
sequence, EMSA (electrophoretic mobility-shift assay) was performed using a γ-32P labeled E 
box-containing double stranded DNA probe. It could be seen on 6% native polyacrylamide gel 
that the c-Myc:Max-E box complex formed two shifted bands (figure 4). The relative mobility 
of the upper band was 0.22. It was previously shown that the c-Myc protein is unstable and 
can not form a homodimer or bind to the E box (Dang 1999). Thus the shifted band was 
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identified as the c-Myc:Max heterodimer. The relative mobility of this band is similar to that 
shown by others for c-Myc:Max (Farina et al. 2004). The relative mobility of the lower band 
was 0.36, and it was identified as the Max:Max homodimer. This was demonstrated using 
purified Max, which gave only one band on the gel at a mobility of around 0.36. BSA was 
used as a negative control for binding activity and showed no binding to the probe (Figure 4). 
It was found that a certain proportion of the Max or c-Myc:Max preparation was in the 
form of big aggregates that did not travel out of the wells during EMSA. These aggregates 
could affect the SELEX procedure if not removed. The Max aggregates could be dissociated 
by diluting 10-fold, but the aggregates of c-Myc:Max did not dissociate after dilution. 
Ultracentrifugation was performed after dialysis to remove the aggregates of c-Myc:Max from 
the preparation. The c-Myc:Max heterodimer itself was not very stable at 4oC. The Max:Max 
homodimer replaced the c-Myc:Max heterodimer with time. Therefore it was necessary to 
make a new protein prep every two to three rounds of SELEX to make sure the correct target 
was available for selection. One possible reason for this dimer substitution is that the 
Myc:Max complex dissociates slowly with time at 4oC. Max forms homodimers much more 
readily than it forms a heterodimer with Myc because the relative concentration of Myc is not 
high enough. This is consistent with previous studies that several micrograms of c-Myc and a 
large molar excess of c-Myc over Max are required to form the heterodimer of c-Myc:Max 
when the two proteins are separately refolded and mixed together. Another explanation of 
these results could be that when Myc and Max dissociate, the Myc protein is not stable as a 
monomer and denatures to form aggregates. Thus the concentration of Myc monomer 
available to form dimers with Max is not high enough, and Max instead will form homodimer.    
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Choices of temperature and KCl concentration of SELEX 
In the original design of the SELEX experiments, 37oC was chosen as the proper 
temperature for selection because it is close to the physiological conditions in vivo. In order to 
make sure the refolded c-Myc:Max complex was active through the SELEX procedure, 2μM 
c-Myc:Max was incubated in SELEX buffer at 37oC for 2 hours in a total volume of 100μl. 
After two hours the sample was diluted into the EMSA binding buffer including 100mM KCl 
and the activity of the c-Myc:Max heterodimer was tested by EMSA using a 0.05μM γ-32P 
labeled E box probe as shown in figure 5. The majority of the protein was present as the 
Max:Max homodimer instead of the c-Myc:Max heterodimer. Room temperature (~24oC) was 
then chosen to replace 37oC in the same incubation procedure of c-Myc:Max in  SELEX 
buffer. When tested at this temperature c-Myc:Max activity was observed on the EMSA gel 
(Figure 5). Therefore we chose 24oC for SELEX. We didn’t try other temperatures. One 
explanation for why 37oC is not a good choice for optimal c-Myc:Max activity may be that at 
37oC or higher temperatures, Max:Max and c-Myc:Max dissociate. The c-Myc monomer is 
not stable and denatures. In the absence of c-Myc, Max will form homodimers (Farina et al. 
2004). 
To further test whether the reconstructed c-Myc:Max was able to bind an E 
box-containing dsDNA oligonucleotide in SELEX buffer, the c-Myc:Max complex was 
incubated with 32P-end-labeled E box probe at a molar ratio of probe to protein of 17:1 in 
SELEX buffer at ~24oC in a total volume of 200 μl for 3 hours. Around 30 μl of the reaction 
solution was then loaded on a 6% native acrylamide gel for EMSA and the complexes were 
resolved by electrophoresis. The results showed smears below the wells instead of a sharp 
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band of c-Myc:Max bound to E box probe. The main difference between the SELEX and 
EMSA binding buffers was the KCl concentration, which was 300mM in SELEX, but 100mM 
in EMSA binding buffer. Because ideal binding activity had been observed in the EMSA 
buffer and not in the SELEX buffer, we changed the KCl concentration from 300mM to 
100mM in the SELEX buffer and did the same incubation and the EMSA experiment. Under 
these conditions, the c-Myc:Max heterodimer showed ideal binding to E box probe (Figure 6). 
These results show that the KCl concentration affects the specific binding of c-Myc:Max to E 
box, which is consistent with previous data (Farina et al. 2004). 
Design of original random pool of SELEX 
The original pool used in the SELEX procedure contained around 1.4x1010 different 
sequences. The pool was amplified by low fidelity PCR from a random pool to increase the 
copy number of each sequence and to introduce more variation into the pool. Each sequence 
of the pool includes 42 random nucleotides surrounded by fixed 5’ and 3’ sequences that could 
be annealed by corresponding primers for amplification as shown in figure 7. 
In theory, (an) aptamer sequence(s) could be selected from the random pool. A 
“decoy” strategy was involved in this design, in which the 5 prime primer contained one 
complement of the E box sequence (CACGTG); the other complement of the E box was 
expected to be present within the random region of certain oligonucleotides in the pool and 
form a stem structure with its complement in the 5’ fixed sequence. This stem structure could 
bind to the c-Myc:Max DNA binding domain. Other parts in the random region were expected 
to evolve into an aptamer, maybe a loop-like structure. Thus we were hoping to select an 
aptamer with two different components that could bind with the c-Myc target protein. The 
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presence of the two linked components with affinity for c-Myc:Max, the primary aptamer 
binding region and the E box containing stem structure, would provide the aptamer with a 
higher affinity for its target than an aptamer with only one binding site. 
The “decoy” strategy has been previously utilized for several targets. Mann et al., 
(1999) targeted E2F, a transcription factor that up-regulates multiple genes' expression related 
to cell cycle and DNA synthesis, with a double-stranded decoy oligodeoxynucleotide. The 
E2F decoy contained a consensus E2F DNA binding site and could bind to E2F to efficiently 
block the activities of some cell-cycle and DNA synthesis related genes (Mann et al. 1999). 
The oncogenic beta-catenin/T-cell factor (TCF), which regulates some cancer-related genes, 
such as Cyclin D1 and c-Myc, is another reported target of the decoy strategy. An 18-mer 
double-stranded DNA decoy of TCF was designed to contain the TCF binding site found in 
target genes' promoter. The TCF decoy efficiently blocked TCF activity and inhibited 
downstream target gene expression (Seki et al. 2006). Generally decoy sequences are the same 
as the recognition sequences of transcription factors in vivo, and a large excess of decoy is 
required to effectively block the target molecules' function. Here we designed a strategy using 
a combination of aptamer and decoy in order to improve the binding affinity of the resulting 
bivalent molecule to the c-Myc:Max target, and to therefore efficiently inhibit the 
transcription factor's function.  
Aptamer Development 
The whole procedure of SELEX is described in figure 8. The method used for aptamer 
selection was filter capture. The nitrocellulose membrane used for filtration has very low 
background binding (less than 2%) of free single stranded DNA molecules, but protein bound 
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oligonucleotides are retained on the filter. For each round of selection, the proper amounts of 
c-Myc:Max and single stranded DNA library, end-labeled with γ-P32,were incubated in 
SELEX buffer at room temperature (around 24oC) for 30 minutes. The mixture was then 
filtered through a nitrocellulose membrane using vacuum (125 mm Hg). The protein-bound 
DNA molecules were retained on the filter and nonbound DNAs went through. Then the 
protein bound DNAs were eluted from the filter with hot urea after washing for three times 
with SELEX buffer and then were amplified by PCR. The size of the PCR product was 86 bp 
on 12% PAGE (Figure 9).  
For PCR, the 5 prime end of the 3 prime primer was biotinylated to allow the PCR 
products to be captured by Dynabead-280 Streptavidin (Dynal Biotech) after incubating in 
B&W buffer (see materials and methods) at 24oC for 30 minutes. After the incubation, the 
PCR product bound beads were resuspended in 1X SSC (see materials and methods) and 
incubated at 95oC for 5 minutes to separate the biotinylated and nonbiotinylated DNA strands. 
It was determined by measuring the cpm values that most of the nonbiotinylated strands, the 
“sense” strand, could be separated from the biotinylated strand. The “sense” strand used for 
the next round of SELEX. During the SELEX procedure, negative selections against the filter 
and Max were included as well as positive selections against c-Myc:Max.    
Two parallel SELEX experiments were performed by Ying Liu and Marjan 
Mokhtarian. Results for Ying Liu’s SELEX are shown in figure 10. Nine rounds of positive 
and seven rounds of negative selection were done, and the highest binding efficiency for 
positive selection was 18% at the 11th round of selection. In positive selections, the ratio of 
target protein to ssDNA pool was from 1:1 to 2.5:1. For negative selections, the first 6 rounds 
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were against filter membrane and in the last round, Max homodimer was used in the SELEX 
to remove the filter binders and Max binders. As we expected, the binding percentage of the 
negative selections was always lower than 3% (Figure 10). This SELEX was not continued for 
further studies. 
For Marjan Mokhtarian's SELEX, seven rounds of positive selections and six rounds 
of negative selections (three against filter, three against Max protein) were performed. The 
starting pool was from 12 cycles of low fidelity PCR using the original random pool; it 
included around 10x1010 DNA molecules. In the fourth round of positive selection, 
double-stranded E box containing oligonucleotide was included to compete with those 
oligonucleotides that bound to Myc:Max based only on the E box binding domain. During the 
whole procedure of SELEX, the selection pressure was not constant. For the positive selection 
in round 1, 2 and 4, the ratio of oligonucleotides to c-Myc:Max protein was 1:1, the ratio in 
round 3 was 1:2.5; in the fifth round of positive selection, the ratio was 3:1 and then 5:1 and 
10:1 in the sixth and seventh round respectively. For the negative selection in round 5, 7 and 8, 
the Max protein was used as the target; the ratio of oligonucleotides to protein was 1:1, 1:4 
and 10:1 respectively.  
As shown in figure 11, the binding efficiency after the last round of positive selection 
was around 27%. For the negative selections against the filter alone, the binding percentage of 
the pool gradually decreased from 20% to 10% then to 3%; for the negative selections against 
Max protein, the percentage also decreased from 30 % to 22. After the 7th round of positive 
selection, the binding efficiency was up to around 27% and the selected single stranded DNA 
molecules were amplified by PCR and cloned into a plasmid using T7 TOPO cloning kit (see 
  
53
 
material and methods). Fifty colonies were cloned and forty-six were sequenced. 
The sequences from the forty-six colonies then were chemically synthesized. The 
synthesized sequences started with the complement of the E box sequence (CACGTG) in the 
5 prime fixed region followed by the 42 random sequences without the 3 prime fixed region as 
shown in Figure 12. The 46 sequences were tested for their ability to bind c-Myc:Max by a 
filter binding assay. Each of the synthesized oligonucleotides was end-labeled by γ-32P and 
incubated with c-Myc:Max (the molar ratio was 1:1), and then was tested the binding 
efficiency using the filter assay. The data from filtration showed that for five of the 
synthesized sequences binding efficiency (bound/unbound) was above 15%. These five 
oligonucleotides were T2-2111, T2-2118, T2-2123, T2-2126 and T2-2134 (refer to Table 1 for 
the sequences).  
EMSA was performed to test the binding ability of the five selected oligonucleotides. 
The five oligosnucleotides were end-labeled with γ-32P. Results (Figure 13) showed that three 
of these five sequences, T2-2118, T2-2123 and T2-2134, could bind to the c-Myc:Max 
complex as shown by the presence of a band at the expected position on the 6% native PAGE. 
Manual alignment of the three oligonucleotides showed that there were some matches, 
especially G, among these sequences with some gaps (Figure 14). The full length sequences of 
the three identified oligonucleotides (including the complete 3' and 5' fixed regions) from 
above then were analyzed using the Mfold program (Zuker 2003) to predict the DNA 
structures in two dimensions (Figure 15). It was found that some concentrations of the 
matches among these sequences existed in a loop or stem-loop region in these molecules, 
which are highlighted with red circles in figure 15. Also, the loop or stem-loop region of each 
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oligo contained several Gs, which indicated that G-quartet structures could be formed in these 
areas.  
A G-quartet is a common DNA binding structure for protein targets (Jing et al. 2004) 
and consists of four guanine bases arranged on the four corners of a square planar (Shafer and 
Smirnov 2000). Thus, it is highly likely that the conserved region in each oligo could play 
some roles in target binding. For example, the thrombin binding aptamer (TBA) was one of 
the earliest studied DNA aptamers that can form G-quartet structure. TBA contains 15 core 
oligonucleotides and forms a unimolecular quadruplex consisting of two G-quartets linked by 
two TT loops and a TGT loop (Macaya et al. 1993).   
We also analyzed the structures of two different truncated versions of W-2118 
(T1-2118, T2-2118), W-2123 (T1-2123, T2-2123), and one truncated version of W-2134 
(T2-2134) using Mfold. The “T1” truncated version of each putative aptamer includes the 
stem-loop portion of the corresponding whole sequence shown in figure 16, and “T2” 
truncated version consists of the complement of the E box sequence following by the random 
region of each corresponding whole sequence (Figure 12 and 16). Data showed that each 
truncated version of the three oligonucleotides contains the same conserved region as the 
corresponding whole sequences (emphasized in red circle) (Figure 16), which indicated that 
these conserved regions could be involved in binding to the target c-Myc protein. 
Binding properties of full length and truncated sequences of selected oligonucleotides 
After predicting the two dimensional structure of the oligonucleotides, we tested the 
binding ability of each oligo to c-Myc:Max including the full length sequences and truncated 
regions determined according to the refolded structure shown in figure 16. The name and 
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sequence of each oligo are shown in Table 1. 
E box GCT CAG GGA CCA CGT GGT CGG GGA TC 
1931 GAG AGA GGT AGG AAT GGC ACG TG 
1201 Bio/ATT CCA GGC AAG GCT GTG TTC 
T2-2111 CAC GTG ACT TCC CGC CCA CTG ACA CCA CGG CAT CCA TTC TCT GTT 
CGT 
T2-2118 CAC GTG ATC GTG GTG GGG GAG GAG GGG AGC CAA GTT CGG TGA ATG 
AG 
T2-2123 CAC GTG TGG GGG GAT ACC CCA GTC GTG CAG CAC TAG GTA CGT TGA 
GTC 
T2-2126 CAC GTG TAC CAG TAC GGC TTC CCG ACT TTC CTA AAC GCA CCC TGA 
TCG 
T2-2134 CAC GTG TAC GTT GGG TGT CAG TGG TCT CAG TGC GGT GGT TCT GGG 
GT 
T1-2118 GGG GAG GAG GGG AGC CAA GTT CGG TGA ATG AGG AAC ACA GCC 
TTG CC 
T1-2123 GCA CGT GTG GGG GGA TAC CCC AGT CGT GC 
W-2118 GAG AGA GGT AGG AAT GGC ACG TGA TCG TGG TGG GGG AGG AGG 
GGA GCC AAG TTC GGT GAA TGA GGA ACA CAG CCT TGC CTG GAA T 
W-2123 GAG AGA GGT AGG AAT GGC ACG TGT GGG GGG ATA CCC CAG TCG TGC 
AGC ACT AGG TAC GTT GAG TCG AAC ACA GCC TTG CCT GGA AT 
W-2134 GAG AGA GGT AGG AAT GGC ACG TGT ACG TTG GGT GTC AGT GGT CTC 
AGT GCG GTG GTT CTG GGG TGA ACA CAG CCT TGC CTG GAA T 
928 GGG GGT AAA GTA TTC CGG GGC GGG A 
Table 1 Sequences of tested oligonucleotides including full length version and two kinds of 
truncated versions. W= full length, T1= truncated version 1, T2 = truncated version 2, which 
includes CACGTG followed by random region. 
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The full length and the two truncated versions of the three selected oligonucleotides 
were end labeled by 32P and tested for binding to c-Myc:Max by EMSA. BSA was used as the 
non-specific binding control for c-Myc:Max. As shown in figure 17 and 18, all of the 
sequences could bind to the c-Myc:Max target protein; the W-2118, T2-2118, T2-2123 and 
T2-2134 could bind to BSA. The end labeled W-2123 and W-2134 were then tested for the 
minimum concentration required for the binding to c-Myc:Max. Results (Figure 19) showed 
that both of the two sequences had c-Myc:Max binding ability at the range from 1μM to 10nM, 
but no BSA binding activity.  
To test if the synthesized oligonucleotides can compete with the E box probe to bind to 
c-Myc:Max, competition EMSA was performed by using end-labeled E box probe and 
unlabeled oligonucleotides as the competitors (Figure 20a). The ratios of each competitor to 
the labeled E box probe were 50:1 and 100:1. Quantitative analysis showed that none of these 
oligonucleotides could effectively compete with the E box for binding to the target protein 
(Figure 20a and 20b). The results of the competition EMSA suggested that the selected 
oligonucleotides could bind to c-Myc:Max complex but not to the E box binding domain on 
the protein. 
The filter binding assay was used to test the binding affinity of the two full-length 
oligonucleotides W-2123 and W-2134 at concentrations ranging from 1nM to 1μM. The 
concentration of c-Myc:Max used in this analysis was 150nM throughout. The amount of 
γ-32P labeled oligonucleotides bound to the target protein was measured at various 
concentrations of each oligonucleotide. From the binding curve of each oligonucleotide, it 
was estimated that the Kd of the full-length oligoW-2134 was around 180 nM, The whole 
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sequence of oligo W-2123 had Kd of about 236nM. These filter binding assays were done by 
Marjan Mokhtarian (Figure 21). 
For developing an aptamer, it is necessary to determine the minimum size of the 
aptamer and to test the binding affinity of aptamer for its target. Two truncated versions 
(T1-2118 and T1- 2123) had 29 and 47 nucleotides and could bind to c-Myc:Max. The lengths 
are in the range of most aptamers; further deletion to get the shortest version and check of the 
binding ability may be necessary. 
The sequences of the current putative aptamers do not include the whole E box region, 
and the data from the competition EMSA demonstrated that the putative aptamers could not 
compete with E box to binding to the c-Myc:Max. These results suggest that the binding site 
of the putative aptamers on the protein target is not in the E box binding domain.   
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CONCLUSIONS AND FUTURE DIRECTIONS 
Our original plan was to select one or more DNA aptamers containing a primary 
aptamer sequence and an E box sequence. The data we obtained showed that there was no E 
box sequence in any of the selected putative aptamers. But from the results of EMSA and filter 
assay, these selected putative aptamers could bind to the c-Myc:Max target protein. Also, the 
EMSA data showed that none of the selected oligonucleotides could compete with E box to 
bind c-Myc:Max target. These results suggest that the selected oligonucleotides bind to some 
other sites on the c-Myc:Max heterodimer instead of the E box binding site. In vivo c-Myc 
cooperates with other cofactors, such as TRRAP, Tip60 through its N-terminal domain to 
regulate gene expression. So these putative aptamers with high binding affinity to c-Myc 
could interfere with the interaction of c-Myc with these cofactors. 
Our current data shows that the Kd of the aptamer W-2123 is about 240 nM and 
W-2134 is 180 nM (The Kd of E box binding to c-Myc:Max is around 100nM). The EMSA 
data showed that W-2123 and W-2134 could bind both c-Myc and Max, so the procedure for 
improving the binding affinity of the aptamers will include optimizing the binding specificity 
by separating the c-Myc and Max binding activity of the aptamers.  
The next step of our future work would be to optimize the binding affinity and 
specificity. To realize this purpose, we could do SELEX on a doped library, which means we 
would synthesize a degenerate aptamer based on the current putative aptamer sequences 
(W-2123 and W-2134). During doping, 10% of the contributing bases in each synthetic 
reaction would be randomly changed to a base other than the original, and 90% would be kept 
the same as in the aptamer sequence. Thus some random mutations would be introduced to the 
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synthesized pool. The two pools of degenerate aptamers (of W-2123 and W-2134) would be 
combined to create a diversified oligonucleotide library. This library would be used in SELEX 
experiments to develop anti-c-Myc or anti-Max aptamers with higher binding affinity than the 
current ones.  
To separate c-Myc and Max binding activity, we would do two parallel SELEX for 
c-Myc:Max (SELEX A) and Max (SELEX B) using the doped library. For the SELEX A, 
c-Myc:Max heterodimer would be used as the target for positive selections, the Max and the 
cellulose nitrate filter support would be used for the negative selections. For SELEX B, Max 
would be used for positive selection and the cellulose nitrate filter support would be used for 
the negative selection. After getting the “winner” target binders with high binding affinity and 
specificity, the minimal binding sequences could be determined by Mfold and then tested by 
EMSA and filter assay to estimate the binding affinity.  
Our next step to further developing an anti-c-Myc:Max aptamer would be create a 
bivalent oligonucleotide by adding an E box (or a Max-binding aptamer if available) to the 
selected aptamer. In this bivalent oligonucleotide, the primary aptamer portion would bind to a 
site on c-Myc outside the E box binding domain and the added E box sequence would bind the 
c-Myc:Max DNA binding domain (or the added Max-binding aptamer would bind to the Max 
protein). In the bivalent molecule, the binding of one of the binding sites to the target protein 
could make the second binding an intramolecular reaction instead of a bimolecular reaction, 
therefore the aptamers would have a higher binding affinity to the c-Myc:Max than an 
aptamer that only has one binding site for its target. 
For making the c-Myc-E box bivalent aptamer, a series of polyAs with different length 
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could be added to the optimized aptamer followed by one complement of the E box 
(5'CACGTG3') which would be annealed with the complementary E box sequence to become 
a double-stranded E box linked to the 3' end of the aptamer. The binding ability of the 
extended aptamers to c-Myc:Max would be tested by EMSA. Competition studies with 
various concentrations of extended aptamers and a certain concentration of radio labeled E 
box could be used to test the ability of the extended aptamers to compete with the E box to 
bind c-Myc:Max. The extended aptamer with the shortest polyA linker and the strongest 
competitive ability to bind to c-Myc:Max would be used for future studies. Once the length of 
polyA linker is optimized, the bivalent aptamer would be synthesized as a single-stranded 
molecule with an E box-hairpin structure at the end. If a Max aptamer were selected, the same 
strategy described above could be used to develop a bivalent c-Myc-Max aptamer by add the 
Max aptamer to the 3' end linked by a proper length of polyA (Figure 22). 
Possible approaches to increasing the bivalent aptamers' stability are circularization 
and chemical modifications. Usually circular DNAs are more stable than linear ones in serum 
and plasma because exonucleases cannot digest circular DNA. Several different modifications 
could be considered to modify the bivalent aptamers, such as 2'O-methoxy-ethyl and 
fluoro-arabino. The main considerations here should be the influence of the modifications on 
DNA stability and on toxicity.  
After a stable bivalent aptamer is available, we would need to develop strategies to 
transfer the single-stranded DNA molecules into proper cell lines. Two delivery strategies 
could be developed. One is to use liposomes as the carriers in an endocytic-dependent way. 
Liposome-mediated delivery is frequently used for transferring oligonucleotides into cells. 
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The delivery procedure can be tested by monitoring the uptake of fluorescence signals from 
fluorescein labeled oligonucleotides. Another strategy is to use peptide-mediated delivery in 
an endocytic-independent way. Several basic peptides have been utilized to transfer 
oligonucleotides into cells. An advantage of this method is that it is possible to deliver DNA 
molecules into both the nucleus and the cytoplasm depending on whether a nuclear 
localization signal is included on the peptide. Also, the delivery procedure will be tested via 
fluorescence signals. An example of this strategy is MPG peptide. It consists of a hydrophobic 
domain, which is from the fusion sequence of HIV gp41, and a hydrophilic domain, which is 
from the nuclear localization signal sequence of the SV40 T-antigen. The MPG peptide can 
tightly bind to single-stranded or double-stranded DNA and ferry the oligonucleotides into 
cells in an endosome-independent way (Simeoni 2003). The effect of the bivalent aptamer on 
the activity of c-Myc:Max would be tested in cultured cells. The continued action of c-Myc 
will affect some cancer-related genes' expression, cell proliferation and cell death procedure. 
So the study of the bivalent aptamer's function could be focused on these aspects.  
To check the effect of the bivalent molecule on inhibiting the c-Myc activity in 
increasing gene expression, we would use PC3 cells that express c-Myc as the host cells and 
then co-transfect the cells with pBTdel208 expression construct and phRL-TK internal control 
plasmid. The pBTdel208 plasmid includes a reporter gene of firefly luciferase and its 
transcription is driven by the truncated 208 bp human telomerase (hTERT) promoter that is 
positively regulated by c-Myc. The phRL-TK internal control plasmid includes a reporter 
gene of sea pansy luciferase that is regulated by the constitutive HSV-thymidine kinase 
promoter in a c-Myc-independent manner. We would treat the host cells with the bivalent 
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c-Myc:Max aptamer and then transfect the cells with the reporter constructs. The influence of 
the aptamer on c-Myc's activity would be detected by measuring the firefly luciferase activity 
relative to sea pansy luciferase activity in the cell lysates. 
To test the bivalent aptamer's effect on cell proliferation, we would use D145 
neuroblastoma cells with high level of c-Myc expression as target cells and use human 
foreskin fibroblast cells without c-Myc overexpression as a control. We would treat the cells 
with optimized concentration of the bivalent aptamer and the cell proliferation rate would be 
determined by counting the cells until the cell reach confluence. 
As a potential anti-cancer drug, the developed bivalent aptamer can be useful in the 
cooperation with other anti-cancer strategies including antisense, RNAi etc. The combination 
of different strategies should be more powerful than single treatment.  
An obvious advantage of using an aptamer compared to other anti-cancer drugs is that 
it can be developed to an allosteric aptamer, which means two different aptamers recognizing 
different targets could be linked together and function simultaneously. For example, the 
c-Myc:Max aptamer could be linked to another aptamer that can specifically bind to an 
anti-cancer drug, such as Gleevec. With this configuration, the binding of the c-Myc:Max 
aptamer to its target will positively regulate the activity of the anti-Gleevec aptamer, which 
means the anti-Gleevec aptamer will be allosterically regulated by the c-Myc:Max aptamer, 
therefore the anti-Gleevec aptamer will work in a c-Myc:Max-dependent way to concentrate 
the anti-cancer drug in cells. The synergistic activity of these two anti-cancer treatments is 
expected to be more effective than only one treatment.         
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APPENDIX 
To express the human c-Myc and Max protein and isolate c-Myc:Max heterodimers 
that bind to E box-involved probes, we tried several different expression vectors and host cells. 
First, we obtained the c-Myc cDNA-containing plasmid pHM6 (pcMYCpHM6), the Max 
cDNA-containing plasmid pHM6 (pcMAXpHM6), and the Max cDNA-containing plasmid 
pSG5puro (pcMaxpSG5puro) from Dr. Clement Lee.  
After checking the sequence of the cDNAs, we subcloned these two cDNA sequences 
into different expression vectors for expression and purification. The c-Myc cDNA in the 
pcMYCpHM6 was subcloned into plasmid pET-21b(+) between BamHI and XhoI to get 
pcMYCpET21b(+) for expression. Primer 171 containing BamH I cutting site and primer 172 
containing Xho I cutting site were individually used as the 5’ and 3’ primers for PCR to 
amplify the c-Myc cDNA in pcMYCpHM6 (Table 2). It was found that the His-tag in 
pET-21b(+) was after the stop codon and thus, this construct could not be used to purify the 
c-Myc protein. Thus, the c-Myc cDNA in plasmid pET21b(+) was then subcloned into 
pET41b(+) to get pcMYCpET41b(+) with His-tag and GST tag coding sequences upstream of 
the start codon of c-Myc cDNA (Figure 23). The Max cDNA was subcloned from 
pcMaxpSG5puro into a pTrcHisA expression vector between the BamHI and EcoRI sites to 
get pcMAXTrcHisA with His-tag coding sequences at 5 prime (done by Tony Peterson) 
(Figure 24). 
After preparing the expression vectors for c-Myc and Max, the two plasmid constructs 
containing c-Myc or Max cDNA were individually transformed into BL21(DE3) and 
XL1-blue host cells for expression and purification (done by Samir Mehanovic). The 
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insoluble c-Myc protein was contained in inclusion bodies and purified under denaturing 
conditions with 6M guanidine-HCl. The Max protein was soluble and directly purified from 
the supernatant of the lysed cells (refer to “Materials and Methods” for details). Ni-NTA was 
used to purify both the proteins. The purified human c-Myc and Max protein were checked by 
Coomassie blue stain and Western blot with the primary mouse anti-his antibody and the 
secondary goat anti-mouse IgG-HRP (Figure 25, 26). 
In figure 25, the left panel shows the Commassie blue stain of c-Myc protein. The 
expected molecular weight was around 100 Kd including the GST-tag and other sequences 
involved in the pET41b(+) vector. The Western blot result shown on the right panel indicated 
that around 70% of the purified protein was c-Myc. In figure 26, the purified Max from XL-1 
blue cells showed around 26 Kd including 6his-tag and some other sequences expressed from 
pTrcHisA vector.   
To get active c-Myc:Max heterodimer, we co-refolded the two purified proteins 
against BC 500 (20 mM Tris-HCl pH7.9, 20% glycerol, 500 mM KCl, 0.05% NP40, 10 mM 
2-mercaptoethano) including 4M urea, BC500 including 2M urea, BC500 including 1M urea, 
BC500 including 0.5M urea , BC500, BC100 (for twice) with 2 hours for each step. The 
activity of the refolded c-Myc:Max heterodimer was checked by EMSA with 6% native PAGE. 
Unfortunately, the refolded product didn't show c-Myc:Max activity but only a blur area 
(figure 27). One possibility was that the GST c-Myc fusion protein folded incorrectly and/or 
that the large GST tag (which included 209 amino acids) may block the dimerization domain 
in the C-terminus of the c-Myc protein so it could not correctly dimerize with the Max protein. 
We switched to another strategy to express the two proteins by using the pETDuet-1 
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expression vector (Novagen) as shown in figure 28. pETDuet-1 includes two multiple cloning 
sites and can co-express two different target proteins in E.coli. Firstly we subcloned the Max 
cDNA from pcMAXpHM6 to pETDuet-1 between SacI and HindIII to get pcMaxpETDuet-1. 
Primer 185 containing the SacI cutting site and primer 186 containing HindIII cutting site 
were individually used to amplify the Max cDNA cut from pcMAXpHM6 (Table 2), then the 
c-Myc cDNA was subcloned from pcMYCpET41b(+) to pcMaxpETDuet-1 between BglII 
and XhoI to get pcMax-Myc-pETDuet-1. The Bgl II-containing primer 187 and Xho 
I-containing primer 188 were used to amplify the c-Myc cDNA, which had been cut from 
pcMYCpET41b(+) (Table 2). The expression vector including c-Myc and Max cDNA was 
then transformed into BL21-CodonPlus (DE3)-RP host cells. Because the Max protein was a 
6his-tag fusion protein and the c-Myc was a GST-tag fusion protein in pETDuet-1 vector, we 
used TALON resin and Glutathione resin in series to purify the co-expressed heterodimer. The 
Coomassie blue staining results (Figure 29) showed two bands at around the 98 Kd and 26 Kd 
position, which should be the c-Myc and Max proteins respectively. The primary rabbit 
anti-c-myc (N-262) polyclonal IgG and the secondary goat anti-rabbit IgG-HRP were used in 
the Western blot for the c-Myc, the primary mouse anti-his antibody and the goat anti-mouse 
IgG-HRP were used in the Western blot for the Max. The results indicated these two proteins 
were correctly expressed in host cells (figure 29). EMSA was utilized to check the activity of 
c-Myc:Max to bind the E box, but it only showed the Max:Max homodimer instead of 
c-Myc:Max heterodimer activity (figure 30). Again the GST tag maybe had some effects on 
the proper folding of c-Myc and Max in this case. 
Finally, we obtained the expression vectors pRSET-His-c-Myc and 
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pET15b(+)-His-Max from Dr. Ernest Martines to individually express the c-Myc and Max 
proteins. We achieved refolding of these two proteins with activity to bind E box probe (refer 
to “Results and Discussion” for details).  
Oligo Sequence 
171 5'-CCC AAG CTG GAT CCC ATG TAC CC-3' (BamH I) 
172 5'-CC+-G CGA ATT CTC GAG GGA GGT ACC-3' (Xho I) 
185 5'-CC CCG AGC TCC TTG ATG AGC GAT AAC GAT G-3' (Sac I) 
186 5'-C CCC AAG CTT TGA TGC ACG TGT AGC G-3' (Hind III) 
187 5'-GG GAA GAT CTA GGA GAT ATA CAT ATG-3' (Bgl II) 
188 5'-CCG CTC GAG ACC AAG CTT CTA CGC ACA AG-3' (Xho I) 
Table2. Oligonucleotide sequences used in amplification and subcloning of c-Myc and Max 
cDNAs. Several primers containing proper enzyme digestion sites were designed to amplify 
the c-Myc and Max cDNA and subclone them into proper expression vectors. The enzyme 
cutting sites are emphasized by bolding and under lines. 
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FIGURES 
 
 
 
 
Figure 1 The structure of BR-HLH-LZ dimerization domain of bHLHZ protein family. Basic 
region, blue; helix1-loop-helix2, violet-purple-magenta; leucine zipper, yellow; DNA 
sequence, orange.  Grandori, Cowley, James and Eisenman (2000). “The Myc/Max/Mad 
network and the transcriptional control of cell behavior.” Annu Rev Cell Dev Biol 16: 653-99. 
Reprinted, with permission, from the Annual Review of cell and Developmental Biology, 
Volume 16 (c) 2000 by Annual Reviews www.annualreview.org 
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Figure 2 Purification and analysis of the human c-Myc protein. Full length c-Myc cDNA was 
expressed in E.coli BL21(DE3)CodonPlusRP as a 6his-tagged fusion protein and purified 
under denaturing conditions with 6M guanidine-HCl. The lysed cells, the supernatant 
obtained after centrifugation of lysed cells and the eluted fractions were analyzed by 
SDS-PAGE. The left panel shows the Coomassie blue staining results, the molecular weight of 
c-Myc protein was around 64 Kd in 15% PAGE, which was the same as in the published 
literature (Farina et al. 2004). The right panel shows the Western blot. Dilution of 1:3000 for 
the primary mouse anti-his antibody and 1:500 for the goat anti-mouse IgG-HRP were used 
for the Western blot.  
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Figure 3 Purification and analysis of human Max protein. Human Max protein was expressed 
in E.coli BL21 (DE3) pLysS as a 6his-tagged fusion protein and purified under 
non-denaturing conditions. The lysed cells and the elution fraction were analyzed by 
SDS-PAGE. The left panel shows the Coomassie blue staining results, the molecular weight of 
Max protein was determined to be around 18 Kd in 15% PAGE. The right panel shows the 
Western blotting results. Dilution of 1:3000 for the primary mouse anti-his antibody and 1:500 
for the goat anti-mouse IgG-HRP were used for the Western blot. The arrows show the 
position of the purified Max protein (Done by Natalya Peretyatko). 
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Figure 4 EMSA of c-Myc:Max and Max:Max complex. The purified human c-Myc and Max 
protein were co-refolded by step-wise dialysis starting with a molar ratio of 3:1. The protein 
mixture was dialyzed in 8 successive steps of 2 hours each against BC500, 4M urea, BC500, 
2M urea, BC500, 1M urea, BC500, 0.5M urea, BC500, BC100 (for twice) then SELEX buffer. 
The Max protein alone without c-Myc was also dialyzed through the same procedure. The 
activity of the human c-Myc:Max and Max:Max complexes were analyzed by 6% 
non-denaturing PAGE using γ-32P end-labeled E box containing dsDNA (refer to Table 1 for 
sequence). The upper arrow points to the c-Myc:Max heterodimer and the lower one points to 
the Max:Max homodimer. The relative mobility of both were the same as published by others 
(Farina et al. 2004).       
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Figure 5 The effect of temperature on c-Myc:Max activity. 2μM c-Myc:Max was incubated in 
SELEX buffer at 37oC or 24oC for 3 hours and then was diluted into EMSA binding buffer. 
The activity of c-Myc:Max heterodimer was tested by EMSA using γ-32P end-labeled E box 
containing dsDNA. The protein complex showed more c-Myc:Max activity after incubation at 
24oC (upper arrow) than after incubation at 37oC. More Max:Max activity was observed at 
37oC (lower arrow). 
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Figure 6 The influence of KCl concentration on binding of c-Myc:Max to the E box. 
c-Myc:Max was incubated with γ32P end-labeled E box probe at a molar ratio of probe to 
protein of 17:1 in SELEX buffer including 100mM KCl or 300mM KCl at ~24oC for 3 hours. 
The activity of c-Myc:Max was tested by EMSA using a 6% native acrylamide gel.  The 
protein heterodimer didn’t show ideal binding when incubated in 300mM KCl (the first two 
lanes), but showed good binding activity when incubated in 100mM KCl (the fourth and fifth 
lanes). The upper arrow points to the c-Myc:Max heterodimer and the lower one points to the 
Max:Max homodimer. These results are consistent with previously reported data (Farina et al. 
2004).     
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Figure7 Diagram of the oligonucleotides in the random pool used in SELEX. In the middle of 
each oligonucleotide in the pool were 42 random nucleotides with equal probability of A, T, C, 
or G at each position. The 5’ and 3’ segments containing fixed sequences could be annealed 
with the correct primer for PCR. In the 5’ segment, there was also one complement of the E 
box sequence, which was CACGTG. 
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Figure 8 Diagram of the SELEX procedure. A filter capture protocol was used for SELEX. 
One round of SELEX included a positive selection against c-Myc:Max and a negative 
selection against the nitrocellulose membrane alone or Max:Max. The ssDNA pool in each 
round of selection was end labeled with 32P. The binding efficiency of the selected pool was 
measured by cpm (counts per minute) value. After each cycle of selection, the selected pool 
was amplified by low fidelity PCR. The 5 prime end of 3 prime primer was biotinylated. After 
the 13th rounds of selection (the binding efficiency was ~27%), the ss DNA pool was cloned 
into the TOPO TA plasmid for sequencing.  
The blue balls denote the c-Myc:Max complex for positive selection, and the red balls stand 
for Max:Max for negative selection. The small red diamond means biotin labeled at the 5’ end 
of 3’ primer for PCR. 
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Figure 9 PCR amplification of a selected single stranded DNA pool. The size of the PCR 
products of the selected pool ran as 86 bp on a 12% PAGE that was staining with ethedium 
bromide. The original random pool was used as the positive control and ddH2O was used for 
the negative control of the selected pool. The DNA marker used was phiX174 DNA/Hinf I 
marker. The 5 prime end of the 3 prime primer was biotinylated to allow the PCR products to 
be captured by Dynabead-280 Streptavidin.  
 
 
 
  
77
 
 
Figure 10 Results of SELEX for selection of an anti-c-Myc aptamer. The basic procedure of 
SELEX is as described in figure 9. Sixteen rounds of selection were performed beginning with 
a random pool of single stranded DNA including 42N in 
sequence:“GAGAGAGGTAGGAATGGCACGT(42N)GAACACAGCCTTGCCTGGAAT”. 
The binding efficiency of each cycle of the selection is shown in the Table under the X axis. 
The blue bars denote the positive selections, dark red bars stand for the negative selections 
against the nitrocellulose filter membrane and the yellow bar denotes the negative selection 
against the Max protein. The ratios on the tops of the bars represent the ratio of protein to 
single-stranded DNA pool used for that round of selection. 
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Figure11 Results of SELEX for isolation of anti-c-Myc aptamers (Done by Marjan 
Mokhtarian). The basic procedure of SELEX was as described in figure 9. Thirteen rounds of 
selection were performed starting with a random pool of single stranded DNA including 42N 
in sequence: “GAGAGAGGTAGGAATGGCACGT (42N) GAACA 
CAGCCTTGCCTGGAAT”. The starting pool was from 12 cycles of low fidelity PCR and 
included around 10x1010 DNA molecules. 
 
 
  
 
 
  
79
 
 
Figure 12 Diagram of the sequences of the synthesized oligonucleotides. The codes on the left 
denote the name of each oligonucleotide. The brown region represents the 42 random core 
sequences that were referenced in figure 10, the green segment denotes one complement of E 
box sequence, CACGTG, and the black lines stand for the 5’ and 3’ primers. The sequence of 
each oligonucleotide was described in Table 2. W=whole, T1=truncated version 1, 
T2=truncated version 2. 
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Figure 13 The binding affinity of five cloned oligonucleotides for c-Myc:Max. The five 
oligonucleotides with binding efficiencies above 15% were end-labeled by polynucleotide 
kinase using γ-32P, and tested by EMSA using a 6% native PAGE. Three of them (T2 2118, T2 
2123 and T2 2134) could bind to c-Myc:Max. The γ-32P end labeled E box probe was a 
positive control for these labeled oligonucleotides. The right arrow shows the position of 
DNA-c-Myc:Max complex, and the left arrow is the position of DNA-Max:Max complex. 
 
 
 
 
  
81
 
 
 
 
Figure 14 Alignment of the full lengths of the three oligonucleotides (W-2118, W-2123 and 
W-2134) that could bind to c-Myc:Max according to EMSA (figure 13). The blue and yellow 
highlighting show some matches among these three oligonucleotides, and the black segments 
identify gaps inserted for alignment. Several Gs were involved in the matches.     
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Figure 15 Structure predictions of the full lengths of the three selected oligonucleotides 
(W-2118, W-2123 and W-2134). The full lengths of the three oligonucleotides that could bind 
to c-Myc:Max based on the results shown in figure 13 were folded using the Mfold program to 
predict the two-dimensional structures. For each oligonucleotide, the structure with the lowest 
free energy is shown. The blue dots denote the matches among the oligonucleotides based on 
the alignment results shown in figure 14, and the red circles show the loop or a stem-loop 
structure in these oligonucleotides in which accumulated matches were found. The sequence 
in the red circle of each oligonucleotide is shown in red letters beside the proposed 
oligonucleotide structure.    
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Figure 16 Structure predictions and comparisons of the full length and truncated versions of 
the three putative aptamers. The full length and truncated versions of the three selected 
oligonucleotides that could bind to c-Myc:Max based on the results shown in figure 13 were 
folded using Mfold program. For each oligonucleotide, the structure with the lowest free 
energy is shown. The W-series show the full length version of each oligonucleotide, the 
T1-series denote the truncated version including the stem-loop structure of each 
oligonucleotide, and the T2-series stand for the truncated version including an E box 
complement and the random region. Diagram of these oligonucleotides are shown in figure 
12.         
 
 
T2-2134 W-2134 
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Figure 17 The binding affinity of two truncated versions of the three selected oligonucleotides 
for c-Myc:Max. The two truncated versions of the three selected oligonucleotides were end 
labeled with 32P and tested for binding affinity for c-Myc:Max by EMSA in a 6% native 
polyacrylamide gel. The 32P end-labeled E box was a positive control and the end-labeled ss 
oligonucleotide “928” was a negative control for the labeled selected oligonucleotides, and the 
BSA was control for c-Myc:Max. The arrow shows the position of DNA-c-Myc:Max complex 
The sequences of each oligonucleotide are described in Table 1. 
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Figure 18 The binding affinity of full length versions of the three selected putative aptamers 
for c-Myc:Max. The full length versions of the three selected oligonucleotides were end 
labeled with 32P and tested for binding affinity for c-Myc:Max by EMSA in a 6% native 
polyacrylamide gel. The 32P end-labeled E box was a positive control and the end-labeled ss 
oligonucleotide “928” was a negative control for the labeled selected oligonucleotides. BSA 
was the control for c-Myc:Max. The arrow shows the position of DNA-c-Myc:Max The 
sequences of each oligonucleotide are described in Table 1. 
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Figure 19 Titration of the full length selected oligonucleotides W-2123 and W-2134. 32P 
end-labeled oligonucleotides W-2123 and W-2134 were diluted to 1.0μM, 100nM, 10nM, 
1nM and 0.1nM. The diluted oligonucleotides were tested for binding affinity to c-Myc:Max 
by EMSA using a 6% native polyacrylamide gel. 32P end-labeled E box was a positive control 
for the labeled oligonucleotides and BSA was a non-specific binding control for c-Myc:Max. 
The upper arrow points at the position of DNA-c-Myc:Max complex, and the lower arrow 
points at the position of DNA-Max complex. 
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Figure 20a Ability of the full length          Figure 20b The selected oligonucleotides 
and truncated versions of the three          from SELEX do not bind to the E box     
oligonucleotides from SELEX to compete    binding domain of c-Myc:Max 
for c-Myc:Max binding. 
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Figure 20a Ability of the full length and truncated versions of the three selected 
oligonucleotides from SELEX to compete for c-Myc:Max binding. 32P end-labeled E box was 
incubated with c-Myc:Max protein with or with out the presence of other unlabeled 
oligonucleotides (competitors). The molar ratios of the labeled E box and each competitor 
were 1:50 and 1:100. The competition between each putative aptamer (competitor) and E box 
was tested by EMSA on a 6% native PAGE. Non-labeled API binding sequence was a control 
for non-specific binding, and non-labeled E box was a positive control for competition. 
 
Figure 20b The selected oligonucleotides from SELEX do not bind to the E box binding 
domain of c-Myc:Max. Quantitative analysis of the data shown in figure 20a   was 
performed by evaluating the amount of 32P end-labeled E box bound to the c-Myc:Max in the 
presence and absence of each non-labeled oligonucleotide. API was used as a control for 
non-specific binding. Non-labeled E box probe was a positive control for specific binding.       
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Figure 21 Binding curves of putative aptamers W-2123 and W-2134. 
The oligonucleotides were end labeled by 32P at the 5 prime end and incubated at 
different concentrations from 1nM to 1μM with a fixed amount of c-Myc:Max (150nM). 
BSA was used to test binding background for each putative aptamer and the background 
binding were subtracted from the c-Myc:Max binding at the corresponding concentration
of putative aptamer. All data were the average of triplicate values. The Kd of each oligo 
was determined by Eadie-Hofstee analysis. (This experiment was done by Marjan
Mokhtarian). 
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Figure 22 Developing a bivalent Myc aptamer. A, c-Myc:Max (red and green dimer) is a 
transcription factor that interacts with many proteins in addition to its DNA recognition 
element, the E box. B, A bivalent circular aptamer binds to the DNA binding site to block E 
box binding and to another site to block protein interactions. C, To create a bivalent aptamer a 
second, E box or Max aptamer sequence will be added to the aptamer. The trial extended 
aptamers will have the second sequence (blue) situated at various distances on a poly 
adenylate tail (tan) from the aptamer (black). D and E, The full E box will be created on the 
trial extended aptamers by annealing with the complementary sequence (blue) and will be 
tested for binding to c-Myc:Max. The cartoon in D shows an aptamer for which the extension 
is not long enough to create a bivalent aptamer. The cartoon in E shows an aptamer for which 
the polyA extension is sufficiently long to create a bivalent Myc-E box aptamer. F, A similar 
approach will be used to create a c-Myc:Max bivalent aptamer by adding a Max aptamer 
sequence at the end linked by a poly A linker of the proper length (By permission from a 
proposal of Dr. Marit Nilsen-Hamilton). 
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Figure 23 Subcloning of the c-Myc cDNA into pET41b(+) expression vector.   
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Figure 24 Subcloning of Max cDNA into pTrcHisA expression vector. The Max cDNA 
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Figure 23 Subcloning of the c-Myc cDNA into pET41b(+) expression vector. The c-Myc 
cDNA was subcloned from plasmid pHM6 into pET21b(+) and then from pET21b (+) into 
pET41b(+) between XhoI and BamHI. The primers used in subcloning were described in 
Table2. The expression vector pET41b(+) including the c-Myc cDNA was transformed into 
host cells BL21 (DE3) to express the c-Myc protein with a 6his tag at the N terminus.       
 
Figure 24 Subcloning of Max cDNA into pTrcHisA expression vector. The Max cDNA was 
subcloned from plasmid pSG5puro into pTrcHisA between BamHI and EcoRI. The 
expression vector including Max cDNA was transformed into XL-1 Blue cells to express Max 
protein with 6his tag at N terminal (done by Tony Peterson).       
 . 
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Figure 25 Commassie blue stain (left) and Western blot (right) analysis of purified c-Myc 
protein from BL21 (DE3). c-Myc cDNA subcloned into pET41b(+) was expressed in 
BL21(DE3). A Ni-NTA column was used for purification under denaturing conditions with 7 
M urea. The Commassie blue stain was used to check the apparent molecular mass of the 
purified c-Myc protein using 15% PAGE. The estimated mass was around 100 Kd. This is a 
fusion protein of c-Myc with a GST tag and a 6His tag as well as some amino acids from the 
expression vector. Dilution of 1:3000 for the primary mouse anti-his antibody and 1:500 for 
the goat anti-mouse IgG-HRP were used for the Western blot. 
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Figure 26 Coomassie blue stain (left) and Western blot (right) analysis for the purified Max 
protein from XL-1 blue. Max cDNA subcloned into pTrcHisA was expressed in XL-1 blue. A 
Ni-NTA column was used for purification under non-denaturing conditions. The Commassie 
blue stain using a 15% PAGE was performed to check the apparent molecular mass of the Max 
protein. The arrows show the position of the purified Max protein; the apparent molecular 
mass was around 26 Kd. This protein was a fusion protein of max with a 6His tag and some 
amino acids from the expression vector. Dilution of 1:3000 for the primary mouse anti-his 
antibody and 1:50,000 for the secondary goat anti-mouse IgG-HRP were used for the Western 
blot.   
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Figure 27 EMSA of the refolded c-Myc:Max heterodimer. Purified c-Myc and Max proteins 
were co-refolded by sequential dialysis against 1) BC500 containing 4M urea, 2) BC500 
containing 2M urea, 3) BC500 containing 1M urea, 4) BC500 containing 0.5M urea, 5) 
BC500, 6) BC100 (twice) with 2 hours for each step. 32P end-labeled E box containing probe 
was used for checking the activity of the refolded product by EMSA on a 6% native PAGE. 
BSA was a negative control for c-Myc:Max. Max was another control for c-Myc:Max.  
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Figure 28 Subcloning of the Max and c-Myc cDNA into the pETDuet-1expression vector to 
co-express these two proteins. The Max cDNA was subcloned from plasmid pHM6 into 
pETDuet-1 between SacI and HindIII, and the c-Myc cDNA was subcloned from pET41b(+) 
into the same pETDuet-1 between Bgl II and XhoI to co-express the Max and c-Myc protein. 
The primers including the proper enzyme digestion sites for PCR and subcloning are 
described in Table 2.  
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Figure 29 Coomassie blue stain (left) and Western blot analysis for the purified c-Myc (middle) 
and the Max (right) expressed from pETDuet-1 expression vector in BL21(DE3)CodonPlus 
RP host cells. TALON and Glutathione resins were used in series to purify the co-expressed 
GST-tagged fusion protein with c-Myc and 6his-tagged fusion protein with Max. The 
Commassie blue stain was used to check the apparent molecular mass of the c-Myc and Max 
proteins after resolving them through a 15% PAGE. The c-Myc fusion protein appeared to be 
about 98 Kd, and the Max fusion protein appeared around 26 Kd including his-tag. Dilution of 
1:100 for the primary rabbit anti-c-myc (N-262) polyclonal IgG and 1:50,000 for the 
secondary goat anti-rabbit IgG-HRP were used in the Western blot for c-Myc; dilution of 
1:3000 for the primary mouse anti-his antibody and 1:50,000 for the goat anti-mouse 
IgG-HRP were used in the Western blot for the Max.   
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Figure 30 EMSA of the co-expressed c-Myc:Max heterodimer. 32P end-labeled E box 
containing probe (refer to Table 1 for the sequence) was used for checking the activity of the 
co-expressed c-Myc and Max by EMSA through a 6% PAGE. BSA was a negative control for 
c-Myc:Max. Max was another control for c-Myc:Max.  
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